Archive for December, 2017

$TEUM Drives Innovation and Bolsters Strength of its Mobile Payment Solution

Entrepreneurial, Hands-on Executive Has Led and Delivered Projects for Fortune 500 Firms in E-Commerce, API Development, Security and Financial Technology Appointment of Davachi as CTO / COO Positions Pareteum Cloud and Application Exchange to Connect Blockchain and Cryptocurrency Transactions Globally

NEW YORK, Dec. 29, 2017 — Pareteum Corporation (NYSE American: TEUM), (“Pareteum” or the “Company”), the rapidly growing mobile Cloud Communications Platform company, announced that it has appointed E-Commerce and Network Security executive Ali Davachi as Pareteum’s Chief Technology Officer and Chief Operating Officer.

Davachi has 20 years of hands-on experience with all facets of complex technology architecture and delivery, working in verticals including finance, healthcare, telecom, and consumer products and services, including security, analytics, big data, workflow orchestration, blockchain and large scale mobile applications for some of the largest companies in the world in these verticals.

Hal Turner, Executive Chairman and Principal Executive Officer of Pareteum commented, “We welcome Ali aboard and are excited to have a technology executive who has worked with the largest credit card company and the largest insurance company in the world join our team. His roll-your-sleeves-up, entrepreneurial approach to executive management exactly fits our culture at Pareteum. As we very rapidly sign multi-year contracts in the MVNO, IoT and API enablement markets with new customers, we are committed to delivering superb operational performance and implementation. Ali is the right person to manage scaling our technology infrastructure and vision to meet Pareteum’s growth needs.”

“Ali has delivered innovative solutions in such a broad spectrum of software and networking environments, and as mobility becomes a “plug-in” to other applications, we needed a brilliant mind to see the many ways our technology and services could be used,” stated Pareteum CEO Vic Bozzo. “His ability to view strategic and tactical initiatives from multiple technical and commercial viewpoints allows him to see opportunities and implement with a new customer for maximum impact. Ali’s depth of experience makes him uniquely qualified to build and manage the teams required to execute the vision for Pareteum.”

“I am excited and honored to join the Pareteum team. Pareteum has a tremendous opportunity in the market today to become the leading provider of cloud-based mobile services. Its products and services are unique and deliver turn-key value, making the company highly competitive in the industry and I am pleased to take these building blocks into applications that are wireless in nature and completely managed by software,” added Ali Davachi, Pareteum’s CTO and COO.

Davachi has 20 years of hands-on experience with all facets of complex technology architecture and delivery, working in verticals including finance, healthcare, telecom, and consumer products and services, including security, analytics, big data, workflow orchestration, blockchain and large scale mobile applications for some of the largest companies in the world in these verticals. Mr. Davachi was previously Chief Information Security Officer and SVP of Technology at Scivantage Inc., which services financial institutions with a SaaS platform delivering investor services. Most recently, Davachi was Founder and CEO of Realware LLC, an enterprise IT and development firm, where he led his staff delivering strategic technology applications in e-commerce, mobile payment management, application development, and managed hosted services to some of the largest credit card companies, insurance companies and global brands. There, he handled all aspects of SaaS infrastructure, database management with Oracle, Microsoft SQL Server, DB2 and Hadoop, and security including secure code initiatives and systems security. Prior, he was Chief Technology Officer at Transactis, responsible for software design and architecture, and Chief Information Officer and Global VP of Process at Wenger Swiss Army.

About Pareteum Corporation
Pareteum Corporation and its subsidiaries provide a complete mobility cloud platform, utilizing messaging and security capabilities for the global Mobile, MVNO, Enterprise, Software-as-a-Service and IoT markets. The Company’s software solutions allow any organization to harness the power of a wirelessly connected world by delivering seamless connectivity and subscriber management capabilities that provides end-to-end control of millions of connected devices. Mobile Network Operator (MNO) customers include Vodafone, the world’s second largest mobile operator by customer count, Zain, one of the largest mobile operators in the Middle East, as well as MVNO customers such as Lebara and Lowi. For more information please visit: www.pareteum.com.

Forward Looking Statements:
Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to Pareteum’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about Pareteum’s industry, management’s beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Because such statements involve risks and uncertainties, the actual results and performance of Pareteum may differ materially from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, Pareteum also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made here. Additional information concerning certain risks and uncertainties that could cause actual results to differ materially from those projected or suggested in Pareteum’s filings with the Securities and Exchange Commission, copies of which are available from the SEC or may be obtained upon request from Pareteum Corporation.

Contractual Revenue Backlog Definition:
Contractual revenue backlog is measured on a forward looking 36 month snapshot view monthly, and, is generated by each of the Company’s Managed Services, Global Mobility Cloud, and Application Exchange & Developer’s Platform customers. The Pareteum multi-year Software-as-a-Service agreements include service establishment and implementation fees, guaranteed minimum monthly recurring fees, as well as contractually scheduled subscribers, in some cases including subscriber usage, during the term of the agreement, and, their resulting monthly recurring revenue. There can be no assurances that we reach the total revenue backlog. The revenue backlog assumes timing of revenue recognition that may vary from actual results.

Pareteum Investor Relations Contact:
Ted O’Donnell
Chief Financial Officer
(212) 984-1096
InvestorRelations@pareteum.com

Hayden IR
(917) 658-7878

Friday, December 29th, 2017 Uncategorized Comments Off on $TEUM Drives Innovation and Bolsters Strength of its Mobile Payment Solution

$NVFY Correction to Previously Announced Las Vegas Product Supply Contract Orders

LOS ANGELES, Dec. 29, 2017 — Nova LifeStyle, Inc. (NASDAQ:NVFY) (“Nova LifeStyle” or the “Company”), a leading U.S.-based, innovative designer and distributor of modern LifeStyle furniture, today announced an update to a previously issued press release from December 18, 2017 regarding orders of Nova LifeStyle’s new “Hollywood Glam Collection” product line from certain hotels in Las Vegas.  At the request of Nova LifeStyle’s customer, the Company has removed their names from its previously issued press release.  The correct press release is as follows:

Nova LifeStyle, Inc. (NASDAQ:NVFY) (“Nova LifeStyle” or the “Company”), a leading U.S.-based, innovative designer and distributor of modern LifeStyle furniture, today announced that the Company has signed initial product supply contracts to provide certain hotels in Las Vegas with Nova-designed and produced “Hollywood Glam Collection” line of furniture products.

Ms. Tawny Lam, Nova LifeStyle’s CEO, stated, “Nova LifeStyle’s ‘Hollywood Glam Collection’ is a tribute to the classic glamour and elegance that recalls the Golden Era of Hollywood. The Company has received considerable interest in this new product category. Customers are particularly drawn to the lush interplay of deep jewel tone velvets, rich woven fabrics, delicate tailoring and injections of gold and polished framing.”

Nova LifeStyle to Debut New Products at the Winter Las Vegas Market Furniture Show

Nova LifeStyle will showcase its new “Hollywood Glam Collection” at the Winter Las Vegas Market furniture show from January 28th to February 1st, 2018.

The Las Vegas Market is held twice a year, displaying the latest styles and trends in home furnishings, décor, and gifts. Historically, Nova has had great successes at showcasing the Company’s new product offering and receiving large orders.

The Winter Las Vegas Market
The Winter Las Vegas Market event: http://www.lasvegasmarket.com/.  Nova LifeStyle’s showroom (under its Diamond Sofa brand) will be located in Building B; 7th Floor; Booth number B-746.  Any interested parties in arranging a private meeting with management can contact Charles Song, Director of Marketing, at marketing@diamondsofa.com.  The Company will be posting pictures of the showroom and event on its website at www.NovaLifeStyle.com.

About Nova LifeStyle
Nova LifeStyle, Inc., a NASDAQ Global Market listed company headquartered in California, is a fast growing, innovative designer and distributor of modern LifeStyle furniture; primarily sofas, dining rooms, cabinets, office furniture and related components, bedrooms, and various accessories in matching collections. Nova’s products are made in the US, Europe, and Asia that include LifeStyle brands such as Diamond Sofa, Nova QwiK, and Bright Swallow International. Nova’s products feature urban contemporary styles that integrate comfort and functionality, incorporating upscale luxury designs appeals to middle and upper middle-income consumers in the U.S., China, Europe, and elsewhere in the world. Visit Nova LifeStyle’s website at www.NovaLifeStyle.com.

Safe Harbor Statement
All statements in this press release that are not historical are forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. There can be no assurance that actual results will not differ from the company’s expectations. You are cautioned not to place undue reliance on any forward-looking statements in this press release as they reflect Nova’s current expectations with respect to future events and are subject to risks and uncertainties that may cause actual results to differ materially from those contemplated. Potential risks and uncertainties include, but are not limited to, the risks described in Nova’s filings with the Securities and Exchange Commission.

Company Contact:
Phone (323) 888-9999
Fax (323) 888-9908
Email info@novalifestyle.com
Friday, December 29th, 2017 Uncategorized Comments Off on $NVFY Correction to Previously Announced Las Vegas Product Supply Contract Orders

$ATRA FDA Clearance to Initiate Two Phase 3 Clinical Studies in EBV+PTLD

– Pivotal studies to commence imminently –

– Primary endpoint results and EU conditional marketing authorization submission
expected in the first half of 2019 –

– Company to host conference call and webcast today at 8:00 a.m. EST –

SOUTH SAN FRANCISCO, Calif., Dec. 29, 2017 —  Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies with tabelecleucel (formerly known as ATA129) in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD). The Company plans to initiate these studies imminently. Tabelecleucel is Atara’s off-the-shelf T-cell immunotherapy in development for the treatment of EBV+PTLD, as well as other EBV associated hematologic and solid tumors.

“We are delighted to have received FDA clearance to start the tabelecleucel Phase 3 clinical studies,” said Isaac Ciechanover M.D., Chief Executive Officer and President of Atara Biotherapeutics. “This achievement included extensive collaboration with the FDA under Breakthrough Therapy Designation and we expect tabelecleucel to be the first off-the-shelf T-cell immunotherapy to begin Phase 3 clinical development in the U.S.  Receiving clearance to initiate these studies is a significant milestone for Atara, and we expect to open our initial clinical sites imminently to serve the substantial unmet need for patients with this life-threatening condition.”

Atara’s tabelecleucel Phase 3 program consists of two global, multicenter, open-label studies:

  • for the treatment of patients with EBV+PTLD following allogeneic hematopoietic cell transplant (HCT) after failure of rituximab (MATCH), and
  • for patients with EBV+PTLD following solid organ transplant (SOT) after failure of rituximab or after failure of rituximab plus chemotherapy (ALLELE).

The Phase 3 studies are expected to open for enrollment in the U.S. imminently and will later expand to include sites in the EU, Canada and Australia.

Results from the first tabelecleucel Phase 3 study to reach the primary endpoint are expected to be announced in the first half of 2019. Atara also plans to submit a tabelecleucel Conditional Marketing Authorization (CMA) application in the EU for patients with rituximab-refractory EBV+PTLD following HCT during the first half of 2019. In addition, Atara plans to continue working closely with the FDA, Health Canada and other global health authorities to make tabelecleucel available to patients as expeditiously as possible.

The primary endpoint of both the MATCH and ALLELE studies is the confirmed objective response rate (ORR), defined as the percent of patients achieving either a complete or partial response to tabelecleucel treatment confirmed after the initial tumor assessment showing a response. The protocols are designed to rule out 20% ORR as the null hypothesis. For example, assuming anticipated enrollment of 35 patients in MATCH, an ORR above approximately 37% would be expected to meet the primary endpoint. In ALLELE, each of two cohorts with an anticipated enrollment of 35 patients will be analyzed independently using the same statistical methodology. Secondary endpoints for both the MATCH and ALLELE studies include duration of response, overall survival, safety, quality of life metrics, and other data in support of potential health economic benefits.

Atara also recently announced positive interim results from an ongoing multicenter expanded access protocol (EAP) study of tabelecleucel for patients with EBV associated cancers, which were presented at the 59th American Society of Hematology (ASH) Annual Meeting. The EAP study findings presented at ASH in patients from the Phase 3 EBV+PTLD study populations were consistent with the tabelecleucel profile observed in previously reported Phase 2 studies conducted by Memorial Sloan Kettering Cancer Center. With the EAP study, Atara has also displayed the ability to rapidly deploy banked, off-the-shelf T-cells to transplant patients in a multicenter setting, and the Company will continue to leverage this experience in the tabelecleucel Phase 3 studies.

Conference Call Information
Atara will host a conference call and webcast today, December 29, 2017, at 8:00 a.m. EST. Analysts and investors can participate in the conference call by dialing (888) 540-6216 for domestic callers and (734) 385-2715 for international callers, using the conference ID 2395468. The live webcast can be accessed on the Events and Presentations page in the Investors and Media section of the Atara website, www.atarabio.com. A replay of the webcast will be available on the Company’s website for 90 days following the live conference call.

About EBV+PTLD
Since its discovery as the first human oncovirus, Epstein-Barr virus (EBV) has been implicated in the development of a wide range of lymphoproliferative disorders, including lymphomas and other cancers. EBV is widespread in all human populations and persists as a lifelong, asymptomatic infection. In immunocompromised patients, such as those undergoing allogeneic hematopoietic cell transplants (HCT) or solid organ transplants (SOT), EBV associated post-transplant lymphoproliferative disorder (EBV+PTLD), represents a life-threatening condition. Median overall survival in patients with EBV+PTLD following HCT who have failed rituximab-based first line therapy is 16-56 days. In EBV+PTLD following SOT, patients failing rituximab experience increased chemotherapy-induced treatment-related mortality compared to other lymphoma patients. One- and two-year survival in patients with high-risk EBV+PTLD following SOT is 36% and 0%, respectively.

About tabelecleucel (formerly known as ATA129)
Atara’s most advanced T-cell immunotherapy in development, tabelecleucel, is a potential treatment for patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC).  In February 2015, FDA granted tabelecleucel Breakthrough Therapy Designation for EBV+PTLD following allogeneic hematopoietic cell transplant (HCT) and in October 2016, tabelecleucel was accepted into the EMA Priority Medicines (PRIME) regulatory pathway for the same indication, providing enhanced regulatory support. Atara also received positive regulatory feedback from Health Canada in September 2017 supporting the submission of tabelecleucel for an expedited approval pathway. In addition, tabelecleucel has orphan status in the U.S. and EU. Phase 3 studies of tabelecleucel in EBV+PTLD following HCT (MATCH study) or solid organ transplant (ALLELE study) are expected to start imminently, and a Phase 1/2 study in NPC is planned for 2018. Tabelecleucel is also available to eligible patients with EBV associated hematologic and solid tumors through an ongoing multicenter expanded access protocol clinical study, positive interim results of which were presented in December 2017 at the 59th American Society of Hematology (ASH) Annual Meeting.

About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The Company’s off-the-shelf, or allogeneic, T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Atara’s T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells. Atara’s most advanced T-cell immunotherapy in development, tabelecleucel (formerly known as ATA129), is being developed for the treatment of patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC). Phase 3 studies of tabelecleucel in EBV+PTLD following an allogeneic hematopoietic cell transplant (MATCH study) or solid organ transplant (ALLELE study) are expected to start imminently, and a Phase 1/2 study of tabelecleucel in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with platinum-resistant or recurrent EBV associated NPC is planned for 2018. Tabelecleucel is also available to eligible patients with EBV associated hematologic and solid tumors through an ongoing multicenter expanded access protocol (EAP) clinical study. Allogeneic ATA188 and autologous ATA190, the Company’s T-cell immunotherapies using a complementary targeted antigen recognition technology, target specific EBV antigens believed to be important for the potential treatment of multiple sclerosis (MS). A Phase 1 clinical study of autologous ATA190 in patients with progressive MS is ongoing. Atara also initiated a multinational, multicenter Phase 1 allogeneic ATA188 clinical study in patients with progressive or relapsing-remitting MS in October 2017. Atara’s clinical pipeline also includes ATA520 targeting Wilms Tumor 1 (WT1) and ATA230 directed against cytomegalovirus (CMV).

Forward-Looking Statements
This press release contains or may imply “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: the Company’s imminent initiation, enrollment, expansion of sites in the EU, Canada and Australia, results and completion of its Phase 3 studies of tabelecleucel, (formerly known as ATA129) in patients with rituximab-refractory Epstein-Barr virus associated post-transplant lymphoproliferative disorder following allogeneic hematopoietic cell transplant or solid organ transplant; plans to continue working closely with the FDA, Health Canada and other global health authorities to make tabelecleucel available to patients as expeditiously as possible;  the expected start of a Phase 1/2 study of tabelecleucel in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with platinum-resistant or recurrent EBV associated NPC in 2018; and the potential advantages of its product candidates.  Because such statements deal with future events and are based on Atara Biotherapeutics’ current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara Biotherapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those discussed under the heading “Risk Factors” in Atara Biotherapeutics’ quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 9, 2017, including the documents incorporated by reference therein, and subsequent filings with the SEC. Except as otherwise required by law, Atara Biotherapeutics disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

INVESTOR & MEDIA CONTACTS:

Investors:
John Craighead, Atara Biotherapeutics
650-410-3012
jcraighead@atarabio.com

Steve Klass, Burns McClellan
212-213-0006 x331
sklass@burnsmc.com

Media:
Justin Jackson, Burns McClellan
212-213-0006 x327
jjackson@burnsmc.com

Friday, December 29th, 2017 Uncategorized Comments Off on $ATRA FDA Clearance to Initiate Two Phase 3 Clinical Studies in EBV+PTLD

$XNY Announces Closing of Securities Purchase Agreement

WUHAN, China, Dec. 29, 2017 — China Xiniya Fashion Limited (“Xiniya” or the “Company” NYSE AMERICAN: XNY), announced today that it has completed the transactions (the “Closing”) contemplated by the Securities Purchase Agreement (the “Purchase Agreement”) with, among others, True Silver Limited, a British Virgin Islands company (“True Silver”) and Honest Plus Investments Limited, a British Virgin Islands company (“Honest Plus”), and the Share Transfer Agreement (the “Divestiture Agreement”) with Qiming Investment Limited, a British Virgin Islands company (“Qiming Investment”), on December 10, 2017.

As a result of the Closing, the Company’s core business has changed from men’s fashion to micro-lending. In addition, all of the current directors and officers of the Company, with the exception of the current Chief Financial Officer, has resigned and new directors and officers have been appointed.

In connection with the closing, on December 28, 2017, the Company effected a ratio change of its American Depositary Share (“ADS”), whereby each ADS represents forty-eight ordinary shares, par value $0.00005 per share (“Shares”) of the Company rather than the current sixteen Shares represented before such ratio change.  In addition, on December 27, 2017, the Company obtained approval from NYSE America LLC (“NYSE American”) to list its ADS on NYSE American.  As a result, the Company has completed the transfer of the listing of its ADS from the New York Stock Exchange (“NYSE”) to the NYSE American, and the Company’s ADS trades on the NYSE American under the symbol “XNY.”

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook” and similar statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

For additional information, please contact:

China Xiniya Fashion Limited
Mr. Chee Jiong Ng
Chief Financial Officer
Telephone: +86 1365 5939 932
Email: ngcheejiong@xiniya.com

Friday, December 29th, 2017 Uncategorized Comments Off on $XNY Announces Closing of Securities Purchase Agreement

$AMBC Purchase of COFINA Bonds and Withdrawal of COFINA Bondholder Objection

NEW YORK, Dec. 28, 2017 — Ambac Financial Group, Inc. (Nasdaq:AMBC) (“Ambac”), a holding company whose subsidiaries, including Ambac Assurance Corporation (“AAC”), provide financial guarantees, announced today that AAC has entered into a purchase agreement with a group of bondholders to purchase certain sales tax revenue capital appreciation bonds (the “COFINA Bonds”) held by such bondholders. With this purchase, when combined with AAC’s existing holdings and other bond purchases made during the quarter, AAC now owns 58% of its insured COFINA Bonds.

In connection with the purchase, the COFINA bondholders have withdrawn with prejudice, their Objection to the Rehabilitator’s September 25, 2017 Motion to Further Amend the Plan of Rehabilitation Confirmed On January 24, 2011 To Facilitate An Exit From Rehabilitation of AAC’s Segregated Account.

About Ambac
Ambac Financial Group, Inc. (“Ambac”), headquartered in New York City, is a holding company whose subsidiaries, including its principal operating subsidiaries, Ambac Assurance Corporation (“AAC”), Everspan Financial Guarantee Corp. and Ambac Assurance UK Limited (“Ambac UK”), provide financial guarantees to clients in both the public and private sectors globally. AAC, including the Segregated Account of AAC (in rehabilitation), is a guarantor of public finance and structured finance obligations. Ambac’s primary goal is to maximize stockholder value by executing the following key strategies: (i) active runoff of Ambac Assurance and its subsidiaries through transaction terminations, policy commutations, settlements and restructurings, with a focus on known and potential future adversely classified credits, that we believe will improve our risk profile, and maximizing the risk-adjusted return on invested assets, (ii) rationalization of Ambac’s and its subsidiaries’ capital and liability structures, enabling simplification of corporate governance and facilitating the successful rehabilitation of the Segregated Account of Ambac Assurance, (iii) loss recovery through active litigation management and exercise of contractual and legal rights, (iv) ongoing review of organizational effectiveness and efficiency of the operating platform, and (v) evaluation of opportunities in certain business sectors that meet acceptable criteria that will generate long-term stockholder value with attractive risk-adjusted returns. Ambac‘s common stock trades on the NASDAQ Global Select Market under the symbol “AMBC”.  The Amended and Restated Certificate of Incorporation of Ambac contains substantial restrictions on the ability to transfer Ambac’s common stock. Subject to limited exceptions, any attempted transfer of common stock shall be prohibited and void to the extent that, as a result of such transfer (or any series of transfers of which such transfer is a part), any person or group of persons shall become a holder of 5% or more of Ambac’s common stock or a holder of 5% or more of Ambac’s common stock increases its ownership interest.  Ambac is committed to providing timely and accurate information to the investing public, consistent with our legal and regulatory obligations. To that end, we use our website to convey information about our businesses, including the anticipated release of quarterly financial results, quarterly financial, statistical and business-related information, and the posting of updates to the status of certain residential mortgage backed securities litigations. For more information, please go to www.ambac.com.

Contact

Lisa A. Kampf
Managing Director, Investor Relations
(212) 208-3177
lkampf@ambac.com

Thursday, December 28th, 2017 Uncategorized Comments Off on $AMBC Purchase of COFINA Bonds and Withdrawal of COFINA Bondholder Objection

$CBMG Announces Closing of $14.5 Million Private Placement Offering

SHANGHAI, China and CUPERTINO, Calif., Dec. 28, 2017 — Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the closing of two private placement transactions pursuant to which it sold an aggregate of 1,208,333 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), to selected key executives and private investors (the “Investors”) at $12.00 per share, for total aggregate gross proceeds of approximately $14.5 Million.

The Company intends to use the proceeds from the financings to fund clinical trials, invest in new product development and expand the Company’s research and development programs.

The issuance of the Shares was made in reliance on the exemption from registration provided by Section 4(a)(2) and Regulation S under the Securities Act of 1933, as amended.

“We are pleased that key executives and investors have shown long-term support for our plans for the three ongoing Chimeric Antigen Receptor T Cell (CAR-T) clinical trials for C-CAR011 in patients with refractory or relapsed Diffuse Large B-cell Lymphoma (DLBCL), adult patients with relapsed or refractory B-cell Acute Lymphoblastic Leukemia (ALL), and patients with B-cell Non-Hodgkin Lymphoma (NHL), as well as human adipose-derived mesenchymal progenitor cell (haMPC) in off-the-shelf allogeneic AlloJoinTM for Knee Osteoarthritis (KOA)”, said Tony (Bizuo) Liu, Chief Executive Officer for the Company. “We expect to keep on providing catalysts to deliver value to our shareholders and continue to build a world-class CAR-T and regenerative biopharmaceutical company. The recent codification of industry regulation for cell therapy products announced by the Chinese government has clarified the development pathway under the Chinese regulatory framework. Additionally, we have a seasoned team, a newly expanded higher throughput manufacturing capacity and a formidable partnership with GE Healthcare and ThermoFisher in automation. These enabling factors have helped raise our confidence in our ability to reach our goal of bringing to market safe and effective cell therapy products for cancer and degenerative diseases to help a large patient population.”

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.  CBMG currently has ongoing CAR-T Phase I clinical trials in China; CARD-1 for Diffuse Large B-cell Lymphoma (DLBCL) and Non-Hodgkin Lymphoma (NHL) and CALL-1 for adult Acute Lymphoblastic Leukemia (ALL), utilizing CBMG’s proprietary and optimized CD19 construct, as well as an ongoing Phase I trial in China for AlloJoin™ (CBMG’s “Off-the-Shelf” Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis (KOA). To learn more about CBMG, please visit www.cellbiomedgroup.com.  

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement our plans, strategies and objectives for future operations, our ability to execute on proposed new products, services or development thereof, results of our clinical research and development, regulatory infrastructure governing cell therapy and cellular biopharmaceuticals, our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of commercialization, our ability to seek intellectual property rights for our product candidates, competition in the industry in which we operate, overall market conditions, any statements or assumptions underlying any of the foregoing and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law. 

Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG

+1 408-973-7884
sarah.kelly@cellbiomedgroup.com

Thursday, December 28th, 2017 Uncategorized Comments Off on $CBMG Announces Closing of $14.5 Million Private Placement Offering

$ZKIN Initial Investment from Blockchain and Crypto Fund Specialists

WENZHOU, China, Dec. 28, 2017 — ZK International Group Co., Ltd. (NASDAQ: ZKIN)  (“ZKIN” or the “Company”), a designer, engineer, manufacturer and supplier of patented high-performance stainless steel and carbon steel pipe products for projects that require sophisticated water or gas pipeline systems, is pleased to announce the receiving of an initial investment from NGST Limited, which is owned by world renowned businessman, politician, advisor, philanthropist and Founder of Blockchain Centre, Antanas Guoga and Exigent Capital, a firm specializing in cryptocurrency trading.

“I am very excited to make a strategic investment in ZK International. Through the implementation of pipeline infrastructure in parts of China, East Asia and Europe, I can appreciate ZK International’s desire to provide clean drinking water to people in geographies where it is desperately needed.  ZK International is already an industry leader, enjoying healthy business relationships with some of the most respected companies in Asia. I look forward to working with the Company and helping it grow,” stated Mr. Guoga.

Mr. Guoga, a member of the European Parliament, is the Founder of Blockchain Centre Vilnius, an incubation hub where blockchain entrepreneurs, developers, investors and regulators connect to share ideas and knowledge on the advancement of blockchain and help blockchain start-ups reach their business goals and potential. Mr. Guoga is also an advisor to Bankera.com, the first digital bank offering traditional banking services for the blockchain era.

Mr. Antanas Guoga has worked on several initiatives to encourage innovation and entrepreneurship throughout Europe.  Mr. Guoga, launched the Coder Dojo Movement and has organized the biggest ICT and entrepreneurship event in the Baltics aptly named “#SWITCH!” This event has grown into one of the largest events having over 200 speakers from 16 countries, including tech giants such as Microsoft, Amazon, Google, Mastercard and Facebook to name a few.

Mr. Jiancong Huang, President and CEO of ZKIN, concluded, “We would like to thank Mr. Antanas Guoga and Exigent Capital for their belief in our Company and our vision, and we are excited to have firms of this calibre believe in what we are accomplishing. We believe ZK will strongly benefit from Mr. Guoga’s extraordinary experience and entrepreneurship, and we look forward to partnering with his team and creating values for our community.”

ABOUT ANTANAS GUOGA

In founding Blockchain Centre (BC) Vilnius — www.bcgateway.eu — Mr. Guoga created the first blockchain technology centre connecting key stakeholders in Asia, Australia, and Europe with the goal to unlock value using blockchain technology in business, finance, and public administration.

A state-of-the-art co-working and shared office space for blockchain start-ups, BC Vilnius joins partner Blockchain’s in Melbourne and Shanghai to incubate and accelerate blockchain start-ups while sharing information about new blockchain opportunities.

Together, the BC’s will be a major force for the development and application of blockchain technology worldwide, completing the age of the internet revolution by empowering social and economic value chains.

Mr. Guoga advises various companies in the blockchain sector.  One of them being Bankera, the first digital bank providing traditional banking services. For more information, please visit Bankera.com. In 2016, Mr. Guoga was included in the POLITICO 40 list as one of the most influential MEPs. In 2017, he was the only member of the European Parliament and Lithuanian to be included in the TOP 200 list of Philanthropists and Social Entrepreneurs, compiled by the positive content portal Richtopia.  He is also the recipient of the Shining World Leadership Award in Australia.

ABOUT EXIGENT CAPITAL

Exigent Capital is a firm that focuses on the exclusive strategies for trading of cryptocurrecies on exchanges around the world. More information can be found at www.exigentcapital.com.

About ZK International Group Co., Ltd.

ZK International Group Co., Ltd. is a China-based designer, engineer, manufacturer and supplier of patented high-performance stainless steel and carbon steel pipe products that require sophisticated water or gas pipeline systems. The Company owns 28 patents, 21 trademarks, 2 Technical Achievement Awards, and 10 National and Industry Standard Awards.  ZK International is preparing to capitalize on the $850 Billion commitment made by the Chinese Government to improve the quality of water, which in its current supply state is 70% unfit for human contact.  ZK International is Quality Management System Certified (ISO9001), Environmental Management System Certified (ISO1401), and a National Industrial Stainless Steel Production Licensee that is focused on supplying steel piping for the multi-billion dollar industries of Gas and Water sectors.  ZK has supplied stainless steel pipelines for over 2,000 projects, which include the Beijing National Airport, the “Water Cube” and “Bird’s Nest”, which were venues for the 2008 Beijing Olympics.  Emphasizing superior properties and durability of its steel piping, ZK International is providing a solution for the delivery of high quality, highly sustainable, environmentally sound drinkable water to not only to the China market but to international markets such as Europe, East Asia and Southeast Asia.

For more information please visit www.ZKInternationalGroup.com. Additionally, please follow the Company on Twitter, Facebook, YouTube, and Weibo. For further information on the Company’s SEC filings please visit www.sec.gov.

Safe Harbor Statement

This news release contains forward-looking statements.  Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to  expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict and many of which are beyond the control of ZK International.  Actual results may differ from those projected in the forward-looking statements due to risks and uncertainties, as well as other risk factors that are described more fully in ZK International’s registration statement on Form F-1 that was filed with the SEC.  Although ZK International believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in forward-looking statements will be realized.  In light of the significant uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by ZK International or any other person that their objectives or plans will be achieved. ZK International does not undertake any obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Investor Contact:

KCSA Strategic Communications
Valter Pinto, Managing Director
PH: +1 (212) 896-1242
ZKInternational@KCSA.com

 

Thursday, December 28th, 2017 Uncategorized Comments Off on $ZKIN Initial Investment from Blockchain and Crypto Fund Specialists

$VSQTF Partners With the North American Bitcoin Conference

VANCOUVER, British Columbia, Dec. 28, 2017 — Victory Square Technologies Inc. (“Victory Square” or the “Company”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) has partnered with the North American Bitcoin Conference (“TNABC”), a part of the World Blockchain Forum. The partnership will see Victory Square and its portfolio companies serving as among the presenters at the conference January 18th-19th in Miami. It will also sponsor a $100,000 investment prize pool for the top three blockchain companies during the ‘Pitch Your ICO’ session.

As the longest running and highest attended financial conference for the bitcoin, blockchain and cryptocurrency industries, the TNABC will bring together over 1,500 major stakeholders in these sectors. TNABC speakers are innovators, thought leaders, and decision makers in the blockchain and cryptocurrency sectors, including past speakers such as Roger Ver (CEO of Bitcoin.com), Halsey Minor (Founder of CNET, Founder of Uphold), Craig Sellars (Co-Founder of Tether), Brock Pierce (Co-Founder of Blockchain Capital), Dr. Moe Levin (Founder of Keynote), Charlie Shrem (Co-founder of Bitinstant), Sasha Ivanov (Founder and CEO of Waves Platform), William Quigley (Founder of WAX), Diego Gutierrez Zaldivar (CEO and Co-Founder of RSK Labs), Adam Perlow (Founder of Zen Protocol), and many other notable figures.

“We’re extremely excited to be playing such a prominent role at the North American Bitcoin Conference,” said Shafin Diamond Tejani, Chief Executive Officer of Victory Square. “It is the premier conference for blockchain and cryptocurrency and we’re looking forward to using the opportunity to engage with some of the most promising startups and respected blockchain thought-leaders in the world.”

Organized by Keynote Events (“Keynote”), the conference will cover a wide array of topics including blockchain technology, Bitcoin and Ethereum, ICOs, token sale mechanics, investing, regulation, startups, disruption, and much more. Notable ICOs that have launched with Keynote include Ethereum ($27 billion market cap), Litecoin ($2.5 billion market cap), Dash ($2 billion market cap), Factum ($70 million market cap), and Blockchain Capital ($30M market cap). Keynote has hosted 12 global blockchain-focused conferences in the last five years in London, Brussels, Dubai, Los Angeles, Amsterdam, and Chicago. At the last Keynote event in London in September 2017, Victory Square portfolio company, FansUnite Media Inc., presented and took home 2nd place for their new sports betting platform using blockchain technology.

A focal point of the Victory Square partnership with TNABC will be the featured ‘Pitch Your ICO’ sessions where Victory Square will gain direct access to the founders of some of the most promising blockchain companies in the world. TNABC has carefully selected over 30 leading blockchain companies from all over the globe to present at the conference to some of the preeminent investors in the space.

“Partnering with Victory Square is a natural fit,” said Dr. Moe Levin, Chief Executive Officer of Keynote. “Victory Square is dedicated to engaging with the world’s leading companies in the blockchain ecosystem, and Keynote is dedicated to showcasing these companies at our events.”

Highlight Video from the last World Blockchain Forum Event in London (September 25 and 26, 2017):

https://www.youtube.com/watch?v=9sfDRVUC3FU

For further information about the Company, please contact:
Howard Blank, Director
Email: ir@victorysquare.com
Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.
Victory Square Technologies is a blockchain-focused venture builder that funds and empowers entrepreneurs to implement innovative blockchain solutions. Victory Square portfolio companies are disrupting every sector of the global economy including Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film. Victory Square has a proven process for identifying game-changing entrepreneurs and providing them with the partners, mentorship and support necessary to accelerate their growth and help them scale globally. For more information, please visit www.victorysquare.com.

ABOUT THE CANADIAN SECURITIES EXCHANGE (CSE)
The Canadian Securities Exchange, or CSE, is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004, the CSE began operations in 2003 to provide a modern and efficient alternative for companies looking to access the Canadian public capital markets. The CSE has not reviewed, nor approved or disapproved the content of this news release.

FORWARD-LOOKING INFORMATION
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Victory Square. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square, including future plans. Although Victory Square believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Victory Square can give no assurance that they will prove to be correct. Forward- looking statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Thursday, December 28th, 2017 Uncategorized Comments Off on $VSQTF Partners With the North American Bitcoin Conference

$CIIX CEO Remains Bullish on Bitcoin and Other Cryptocurrencies

  • Warren Wang, CEO of CIIX, said in a podcast interview that investors in China and the Chinese-speaking community in the U.S. and Canada want to learn more about bitcoin, cryptocurrencies
  • CIIX doubles down on commitment to its bitcoin division, adding a bitcoin ATM in its California headquarters and broadcasting a daily video from the NYSE called ‘Bitcoin Multimillionaire’
  • Company’s goal in FY2018 is profit, lower costs and a greater than 100 percent YOY sales increase

ChineseInvestors.com, Inc. (OTCQB: CIIX) CEO Warren Wang remains bullish on the future of bitcoin and other cryptocurrencies, and he recently said in a podcast interview that the Chinese-speaking community worldwide is eager to learn more about buying and managing digital currencies. Despite China’s ban on trading cryptocurrencies on a regulated exchange, he noted, many Chinese investors are buying and selling them on unregulated offline platforms.

In an interview with the Bad Crypto Podcast (http://nnw.fm/oO7WI), Wang explained that the Chinese investor is an important target for cryptocurrency entrepreneurs. “The Chinese investor is an advocate of gambling,” he explained. “Most today trade bitcoin and other cryptocurrencies on…

Read more »

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Thursday, December 28th, 2017 Uncategorized Comments Off on $CIIX CEO Remains Bullish on Bitcoin and Other Cryptocurrencies

$DRIO Granted Another U.S. Patent Strengthening its Core Technology

CAESAREA, Israel, Dec. 27, 2017 — DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced the U.S. Patent and Trademark Office has issued the Company patent #9832301 titled “Systems and Methods for Adjusting Power Levels on a Monitoring Device.”

DarioHealth uses this patented technology to enhance the way its smart meter communicates with users’ smartphone devices. In the U.S. market, the Dario™ Blood Glucose Monitoring System connects to a smartphone via a coin-sized dongle that does not require a battery for operation; rather, it relies on the smartphone’s battery as its power source. In the effort to reduce battery-dependence and ensure 100% real-time data capture, the application is able to monitor and adjust power levels on smartphones accordingly to enable sufficient output with minimal reliance.

Dror Bacher, COO and Vice President of R&D at DarioHealth, commented, “We are very excited to finish off 2017 with this news. This patent has already been part and parcel of the Dario Blood Glucose Monitoring System since it entered the U.S. market and showcases our commitment to further enhancing our core technologies on our native mobile solutions.

“With this patent, DarioHealth strengthens its IP rights and enables us to be compatible with more devices. DarioHealth is a unique company that is building value for its investors, as it continues to make new technological applications in the chronic disease management space in general and specifically in the diabetes space.”

About DarioHealth Corp.

DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, the content of which is not part of this news release, visit http://mydario.investorroom.com/.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when it describes further enhancing its core technologies on its native mobile solutions and building value for its investors, as it continues to make new technological applications in the chronic disease management space in general and specifically in the diabetes space. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact: Shmuel Herschberg, Marketing Director, shmuel@mydario.com, 1-914-775-5548

DarioHealth Public Relations Contact: Terese Kelly, Rosica PR, terese@rosica.com, 1-201-843-5600

DarioHealth Investor Relations Contact: Stephen Hart, Hayden IR, DRIO@HaydenIR.com, 1-917-658-7878

Wednesday, December 27th, 2017 Uncategorized Comments Off on $DRIO Granted Another U.S. Patent Strengthening its Core Technology

$WATT Up 76% As It Gets First Green Light For Charge At A Distance Software

Energous Corporation (NASDAQ:WATT) just got its first certificate from the FCC, Federal Communications Commission, for approval of its new technology charging software. As wireless charging has become the newest and most popular choice for charging devices, Energous wants to introduce a brand new non-contact charging.

The company’s new system does not require any physical contact between the charger and the device. It can work up to distances of 15 feet and eliminates the hassle of having to physically charge all devices such as cell phones, tablets, TVs, earbuds, speakers, smart lighting, and laptops.

This announcement just broke this morning as the San Jose based startup broke the news of their approval certificate for its WattUp Mid Field transmitter. Since then, Energous Corporations stock has risen more than 76% and is now selling at $15.57, a share.

The primary functioning of this new charging system is based on a specific transmitter that converts electricity into radio frequencies and then shoots those frequencies to nearby devices. All devices have to be outfitted with a specific receiver and currently, and multiple devices can be charged simultaneously, within 15 feet of the transmitter. The company hopes that one day, it may extend beyond 15 feet and potentially charge a whole household.

This specific system is manufactured similarly to that of normal Wifi which means the transmitter is no way linked to the functioning of the charging system. The company has not yet launched its system yet but instead intends on showcasing it at the CES 2018, which will be held mid-January in Las Vegas, Nevada.

Energous Corp. hopes to bring this technology and system to sale at the end of 2018 or the beginning of 2019. In the meantime, the company plans on continually testing the product to make necessary adjustments and upgrades before its commercial launch.

Wednesday, December 27th, 2017 Uncategorized Comments Off on $WATT Up 76% As It Gets First Green Light For Charge At A Distance Software

$GOHE CEO, James H., Reflects on the Highlights, and Achievements of 2017

SAN DIEGO, Dec. 27, 2017 — via OTC PR Wire —  Global Payout, Inc. (OTCPink:GOHE) (“Global, the Company”) is pleased to provide its valued shareholders and interested parties with the following 2017 year-end letter of review from the Company’s CEO, James H.:

Dear Valued Shareholders and Interested Parties:

For those of you who may have been following our news and updates throughout the year, you know 2017 has been an especially active, yet successful year for both Global Payout and our majority owned subsidiary, MoneyTrac Technology, Inc.

In January, my executive team and I laid-out a detailed list of objectives we believed were imperative to achieve in 2017 in order for the Company to position itself to drive revenue and truly distinguish the brand from all competitors in the Fintech market space. In reflecting upon the year that was, I can not only report with that we successfully achieved our objectives, but, we have surpassed them in ways I could not have imagined.

Without question, one of the most critical events of the year involved the appointment of Ms. Vanessa Luna as Global’s Chief Operating Officer. Ms. Luna’s experience and tenacity made an immediate impact within our Company’s internal operations as she began to map out the path our Company would need to achieve each of our objectives.

Recognizing the gap between adequate financial technology solutions and the rapidly expanding, multi-billion-dollar cannabis industry, a collective decision was made in March to spinout our majority owned subsidiary, MoneyTrac Technology to begin serving the underserved businesses of the cannabis industry. With this spinout, Ms. Luna was transitioned over to MoneyTrac to serve as COO and to help spearhead the development of the brand by leveraging the many different strategic partnerships she had already developed within the industry.

Once given the green light, Ms. Luna was off to the races, cultivating several new, and incredibly significant partnerships for MoneyTrac. These partnerships include greenRush, BlazeNow, High Grade Management Group, and PotSaver, with whom she facilitated a majority acquisition in October. These partnerships, combined with several other important developments throughout the year, have effectively positioned MoneyTrac to generate revenue and become a recognized leader of a variety of service and solution offerings within the cannabis industry.

Significant groundwork was also laid in 2017 to support the growth and expansion of our logistics division. This includes critical enhancements made to our Global Reserve Platform that will serve as the foundation for a new logistics-focused subsidiary. An impressive executive team will lead this subsidiary in 2018 to carve-out a distinctive niche within the trillion-dollar logistics industry.

Focus during the 4th quarter of the year was also placed on positioning the Company to successfully complete its Form 10-K Audit. I cannot express how much gratitude I have for our internal operations team, who have worked so diligently over the past several weeks to see this through. I am highly optimistic that this will be completed in the coming weeks and will provide us with an opportunity to be up-listed to other platforms offered by the OTC Markets Group, such as the OTCQB and OTCQX.

The coming weeks will also be filled with some strategic changes and updates that will play a very important role in helping to shape the Company and its subsidiaries to meet future objectives. It is with great pleasure and excitement that I share that next week we anticipate announcing one of these changes, a passing of the baton that will be instrumental in guiding our Company’s vision and objectives into a very prosperous future.

In closing, I would like to offer my sincerest thanks and appreciation to my wonderful team of executives and employees who are a shining example of hard work and dedication. I would also like to extend a special thank you to our valued shareholders who continue to demonstrate their loyalty and support. I can assure you, the best is very much yet to come.

Cheers to a very prosperous New Year!

Sincerely,

James L. H., CEO

About Global Payout, Inc. (OTC Pink:GOHE)

Since the Company’s inception in 2009, Global Payout, Inc. has been a leading provider of comprehensive and customized prepaid payment solutions for domestic and international organizations distributing money worldwide. In 2014, Global introduced its first online payment platform called the Consolidated Payment Gateway (CPG), which allowed its enterprise clients to transfer money to international bank accounts, mobile accounts, and prepaid card accounts. The development of the CPG became the foundation for the introduction of its new, state of the art FINTECH payment system in 2017, for both online and mobile applications to allow account holders to maximize an expanded suite of financial services and minimize operational costs. Global will continue to offer their FINTECH payment system to many vertical markets for support of foreign currency exchange and digital currency, including ongoing support of the banking industry and international governments.

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.

Public Relations and Media Contact:

Global Payout

www.GlobalPayout.com

619.795.5810 Office

Information@GlobalPayout.com

Communications Contact:

NetworkNewsWire (NNW)

New York, New York

www.NetworkNewsWire.com

212.418.1217 Office

Editor@NetworkNewsWire.com

Wednesday, December 27th, 2017 Uncategorized Comments Off on $GOHE CEO, James H., Reflects on the Highlights, and Achievements of 2017

$DMPI Fast Track Designation for VAL-083 in Recurrent Glioblastoma

Supports Lead Program, VAL-083, in Ongoing Clinical Trials –

VANCOUVER, British Columbia and MENLO PARK, Calif., Dec. 26, 2017 — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s lead product candidate, VAL-083, in recurrent glioblastoma (rGBM).

“The Fast Track designation marks an important milestone in the development of VAL-083 as a potential new therapy for cancer patients with limited or no treatment options,” said Saiid Zarrabian, interim chief executive officer at DelMar.  “We appreciate the FDA’s recognition that the VAL-083 program addresses a significant unmet need in rGBM as we continue to evaluate this agent in patients with multiple tumor types.”

This Fast Track status applies to two ongoing clinical trials sponsored by DelMar Pharmaceuticals to evaluate VAL-083 as a potential treatment for rGBM.  These trials include:

  • A Phase 2 study in bevacizumab-naïve MGMT-unmethylated GBM patients conducted in collaboration with The University of Texas MD Anderson Cancer Center; and
  • A Phase 3 study of patients whose disease has progressed following prior treatment with temozolomide and bevacizumab (the STAR-3 trial).

Fast track designation is designed to expedite the review of drugs that show promise in treating life-threatening diseases and address unmet medical needs, with the goal of getting new treatments to patients earlier. Fast Track designation provides sponsors with an opportunity for increased frequency of communication with FDA to ensure an optimal development plan and to collect appropriate data needed to support drug approval.

Additional benefits of the Fast Track designation may include an Accelerated Approval, a Priority Review, and a Rolling Review. Accelerated Approval is granted to drugs that demonstrate an effect on a surrogate, or intermediate endpoint reasonably likely to predict clinical benefit. Priority Review shortens the FDA review process for a new drug from ten months to six months, and is appropriate for drugs that demonstrate significant improvements in both safety and effectiveness of an existing therapy. Rolling Review provides a drug company the opportunity to submit completed sections of its New Drug Application (NDA) for review by the FDA. Typically, NDA reviews do not commence until the drug company has submitted the entire application to the FDA.  Through the Fast Track designation, the FDA attempts to ensure that questions raised during the drug development process are resolved quickly, often leading to earlier approval and increased access for patients.

Outside of rGBM, DelMar has initiated a Phase 2 clinical trial of VAL-083 in newly-diagnosed MGMT-unmethylated GBM.  DelMar also recently received notice of allowance from the FDA of an IND for a Phase 1/2 trial of VAL-083 in patients with recurrent platinum-resistant ovarian cancer.

“Our ongoing VAL-083 clinical development program is supported by extensive preclinical research into the agent’s unique mechanism of action, as well as promising data from prior clinical trials sponsored by DelMar and the National Cancer Institute,” added Mr. Zarrabian.  “We are enthusiastic about the potential of VAL-083 to offer a meaningful clinical benefit to patients with rGBM and for the opportunity to expedite the regulatory process through the FDA’s Fast Track program.”

About VAL-083

VAL-083 (dianhydrogalactitol) is a “first-in-class,” DNA-targeting agent that introduces interstrand DNA cross-links at the N7-position of guanine leading to DNA double-strand breaks and cancer cell death. VAL-083 has demonstrated clinical activity against a range of cancers including GBM and ovarian cancer in historical clinical trials sponsored by the U.S. National Cancer Institute (NCI).  DelMar has demonstrated that VAL-083’s anti-tumor activity is unaffected by common mechanisms of chemoresistance in vitro. Further details regarding these studies can be found at http://www.delmarpharma.com/scientific-publications.html.

VAL-083 has been granted an orphan drug designation by the U.S. FDA Office of Orphan Products for the treatment of glioma, medulloblastoma and ovarian cancer, and in Europe for the treatment of malignant gliomas.

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals is focused on the development and commercialization of new therapies for cancer patients who have limited or no treatment options.  By developing an understanding of tumor biology and mechanisms of treatment resistance, the Company identifies biomarkers to personalize new therapies in indications where patients are failing, or have become intolerable to modern targeted or biologic treatments.

The Company’s current pipeline centers around VAL-083, a “first-in-class,” small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers including central nervous system, ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head & neck) in U.S. clinical trials sponsored by the NCI.  Based on DelMar’s internal research programs and these prior NCI-sponsored clinical studies, the Company is conducting clinical trials to support the development and commercialization of VAL-083 across multiple oncology indications to solve significant unmet medical needs.

DelMar is currently studying VAL-083 in a Phase 3 clinical trial for GBM patients whose tumor has recurred following treatment with temozolomide and bevacizumab.  VAL-083 is also being studied in two collaborator-supported, biomarker driven, Phase 2 clinical trials for MGMT-unmethylated GBM.   Overcoming MGMT-mediated resistance represents a significant unmet medical need in the treatment of GBM.  DelMar also recently announced the allowance of a separate IND for VAL-083 as a potential treatment for platinum-resistant ovarian cancer.

Further information on DelMar’s clinical trials can be found on clinicaltrials.gov:  https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs

For further information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989.

Connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

Tuesday, December 26th, 2017 Uncategorized Comments Off on $DMPI Fast Track Designation for VAL-083 in Recurrent Glioblastoma

$WATT Industry-First FCC Certification for Over-the-Air, Power-at-a-Distance Wireless Charging

Approval marks major step forward for smart home, IoT and mobile devices Conference Call Scheduled for Dec. 27, 5:30 a.m. PT

SAN JOSE, CA–(December 26, 2017) – Energous Corporation (NASDAQ: WATT), the developer of WattUp®, a revolutionary wire-free, power-at-a-distance charging technology, today announced Federal Communications Commission (FCC) certification of its first-generation WattUp Mid Field transmitter, which sends focused, RF-based power to devices at a distance. As the first FCC certification for power-at-a-distance wireless charging under Part 18 of the FCC’s rules, this development represents a new era of wireless charging, and opens up a tremendous opportunity for the electronics industry.

Energous’ WattUp Mid Field transmitter underwent rigorous, multi-month testing to verify it met consumer safety and regulatory requirements. As the first Part 18 FCC approved power-at-a-distance wireless charging transmitter, the certification marks a significant milestone for the consumer electronics industry and paves the way for future wireless charging ubiquity for nearly any small electronic device, including smartphones, tablets, fitness trackers, smart watches, earbuds, wireless keyboards and mice, smart speakers and more.

The company’s WattUp Mid Field transmitter can deliver power via radio frequency (RF) energy to WattUp-enabled electronic devices at a distance of up to three feet. As the only technology that can do both contact-based and non-contact-based wireless charging, as well as charge multiple devices at once, WattUp is highly scalable and automatically charges devices, as needed, until they are topped off. While older charging technologies allow for only contact-based charging, Energous is the only company to achieve Wireless Charging 2.0 to-date, which is the ability to charge devices both at contact (including fast charging large battery devices such as smartphones and tablets), as well as power-at-a-distance. Similar to WiFi, the WattUp ecosystem ensures interoperability between receivers and transmitters, regardless of the manufacturer, making the entire ecosystem flexible and accessible for consumers and manufacturing partners.

“Older wireless charging technologies have received limited adoption over the past 15 years, and are confined to contact-based charging only. The FCC certification of Energous’ power-at-a-distance wireless charging transmitter is a major market milestone. It opens up options, outside of just contact-based charging, to Wireless Charging 2.0: an ecosystem where devices can be charged both, via pad and at a distance,” said Stephen R. Rizzone, president and CEO of Energous. “Untethered, wire-free charging — such as charging a fitness band even while wearing it — is exactly what consumers have been waiting for. We are now in a position to move our consumer electronics, IoT and smart home customers forward at an accelerated pace.”

“WattUp from Energous represents an incredibly positive lifestyle change,” said Martin Cooper, Energous Board of Directors member and ‘Father of the Cell Phone’ — a pioneer and visionary of the wireless industry. “This ground-breaking technology allows users to automatically charge their WattUp-enabled devices without having to remove them from their wrist or pocket, plug them in or place them on a mat to charge, freeing them from ever having to think about charging their devices again.”

WattUp transmitter technology will continue to advance in both power, distance, efficiency and scale, with applications that could include integration into the bezel of computer monitors, soundbars, smart speakers, TVs, smart lighting, and other electronics in the home, office and beyond.

“Providing meaningful power-at-a-distance is a real game changer for wireless charging,” said Mark Tyndall, senior vice president corporate development and strategy, Dialog Semiconductor. “As the strategic partner and exclusive world-wide supplier of Energous’ WattUp technology, Dialog provides early adopters with the assurance of chip supply and support that comes from a top tier semiconductor company that ships millions of chips each month into some of the world’s most demanding customers.”

This represents the first time FCC equipment certification has been awarded to any device that charges wirelessly at a distance, and operates under Part 18 of the FCC’s rules. The FCC’s Part 18 rules permit higher-power operations than are permitted under the Part 15 rules that have been used to approve other at a distance charging devices.

The company will be demonstrating its very latest WattUp technology at CES 2018, the world’s largest consumer electronics show, January 9-12 in Las Vegas, NV. To learn more about Energous, please visit Energous.com or follow the company on Twitter, Facebook, Instagram or LinkedIn.

Conference Call

Energous will hold a conference call and webcast on Wednesday, December 27, 2017 at 5:30 a.m. PT to review the FCC certification details in greater depth and answer questions. To join the conference call:
Phone: 866-235-9911 (domestic); 412-317-1083 (international)
Replay: Accessible through January 10, 2018
877-344-7529 (domestic); 412-317-0088 (international); passcode 10115359
Webcast: Accessible at ir.energous.com; archive available for approximately one year

About Energous Corporation

Energous Corporation is the developer of WattUp® — an award-winning, wire-free charging technology that will transform the way consumers and industries charge and power electronic devices at home, in the office, in the car and beyond. WattUp is a revolutionary radio frequency (RF) based charging solution that delivers intelligent, scalable power via radio bands, similar to a Wi-Fi router. WattUp differs from older wireless charging systems in that it delivers contained power-at-a-distance — thus resulting in a wire-free experience that saves users from having to remember to plug in their devices. For more information, please visit Energous.com.

Safe Harbor Statement

This press release contains forward-looking statements that describe our future plans and expectations. These statements generally use terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or similar terms. Examples of our forward-looking statements in this release include statements in quotations from management and statements about our partnership with Dialog and development of market demand, production and deployment of products. Our forward-looking statements speak only as of this date; they are based on current expectations and we undertake no duty to update them. Factors that could cause actual results to differ from what we expect include: unexpected delays in our ability to develop commercially feasible technology; uncertain timing of further regulatory approvals; timing of customer orders and success of customer products; our dependence on distribution partners; market acceptance of our technology; and intense industry competition. We urge you to consider those factors, and the other risks and uncertainties described in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, in evaluating our forward-looking statements.

Energous Public Relations
PR@energous.com
408-963-0200

Investor Relations Contact:

Bishop IR
Mike Bishop
(415) 894-9633
IR@energous.com

Tuesday, December 26th, 2017 Uncategorized Comments Off on $WATT Industry-First FCC Certification for Over-the-Air, Power-at-a-Distance Wireless Charging

$TEUM Adds Blockchain Settlement for Cryptocurrency to Its Global Cloud Platform

Smart City, Mobile Virtual Network Operators and Internet of Things Service Providers now Able to Exchange Digital Currency and Subsidize Service

NEW YORK, Dec. 26, 2017 — Pareteum Corporation (NYSE American: TEUM), (“Pareteum” or the “Company”), the rapidly growing mobile Cloud Communications Platform company, today announced that it has completed development enabling it to add support of Blockchain technology to its billing and settlement services. This newest service capability enables Pareteum customers to participate in the transformational “Digital Economy Monetization to the Cloud” and now accept and process Bitcoin, Ethereum, Litecoin, Airtokens and other forms of cryptocurrencies.

According to Coinschedule, $287 million of cryptocurrency transactions or 7.8% of ICOs involved payments in 2017. This evolution began in 2016, noted Coinschedule, within the mobile payment industry with more than 50% of mobile users making a mobile payment, and it has continued in 2017 with the market expanding to $60 billion in mobile payments. Perhaps the biggest disrupter may be the technology behind digital currency. Blockchain has been noted as the potential foundation for building a new generation of transactional applications that establish trust and transparency while streaming business processes, which is critical to advancing adoption of mobile payments among consumers and businesses.

The new feature being offered to all Pareteum’s Global Mobility Cloud customers will allow them to not only accept the cryptocurrencies but also to perform payment processing and settlements with their partners in any currency. For example, in the case of Smart Cities in emerging markets, creation of their own local cryptocurrencies is now a reality, facilitating primary economic benefit with the cities for their citizens. Last year, Pareteum announced a partnership with Airfox to integrate their advertising subsidy platform into the Application Exchange and Developer’s Platform exchange based on the requirement for advertising to subsidize the costs of growing data service usage. Since then subsidies have gone beyond advertising and into micro-loans and cryptocurrency as the mobile phone penetrates more of daily life.

Vic Bozzo, CEO of Pareteum stated, “The demand in the mobile market for digital wallet applications has quickly morphed into a requirement to process and settle all forms of currency and an entire eco-system of applications relying on purely digital settlement has emerged. It’s a natural requirement of any Mobile Platform provider to support this move as many mobile applications become reliant on mainstream digital currency and other applications begin to create their own.”

Hal Turner, Executive Chairman and Principal Executive Officer of Pareteum, added, “We have sold solutions that take us, through our cloud services, into Smart Cities and cryptocurrency payment capabilities. It’s not hard to imagine that we can live in an entire digital universe where all of our transactions may be managed through your own personal mobile phone, with secure identity management and digital payments. In thinking about this scenario, where essentially your mobile phone is your bank, without bricks and mortar, it’s possible that throughout the day you may have earned enough digital currency through your transactions to be rewarded with that coffee or snack or phone minute or that extra megabyte of data. We envision a time in the not too distant future when Pareteum could create its own currency payments and settlements among the millions of subscribers on its platform globally. As we consider the new global mobile landscape, and Pareteum’s service and capabilities developments in 2017, which have opened doors for us in the Internet of Things (IoT), Smart Cities, and use of Artificial Intelligence (AI) and Machine Leaning (ML) creating predicative analytics for the vast amounts of digital data we are capable of securely processing, we maintain an optimistic view towards 2018 and beyond.”

About Pareteum Corporation

Pareteum Corporation and its subsidiaries provide a complete mobility cloud platform, utilizing messaging and security capabilities for the global Mobile, MVNO, Enterprise, Software-as-a-Service and IoT markets. The Company’s software solutions allow any organization to harness the power of a wirelessly connected world by delivering seamless connectivity and subscriber management capabilities that provides end-to-end control of millions of connected devices. Mobile Network Operator (MNO) customers include Vodafone, the world’s second largest mobile operator by customer count, Zain, one of the largest mobile operators in the Middle East, as well as MVNO customers such as Lebara and Lowi. For more information please visit: www.pareteum.com.

Forward Looking Statements:
Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to Pareteum’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about Pareteum’s industry, management’s beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Because such statements involve risks and uncertainties, the actual results and performance of Pareteum may differ materially from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, Pareteum also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made here. Additional information concerning certain risks and uncertainties that could cause actual results to differ materially from those projected or suggested in Pareteum’s filings with the Securities and Exchange Commission, copies of which are available from the SEC or may be obtained upon request from Pareteum Corporation.

Contractual Revenue Backlog Definition:
Contractual revenue backlog is measured on a forward looking 36 month snapshot view monthly, and, is generated by each of the Company’s Managed Services, Global Mobility Cloud, and Application Exchange & Developer’s Platform customers. The Pareteum multi-year Software-as-a-Service agreements include service establishment and implementation fees, guaranteed minimum monthly recurring fees, as well as contractually scheduled subscribers, in some cases including subscriber usage, during the term of the agreement, and, their resulting monthly recurring revenue. There can be no assurances that we reach the total revenue backlog. The revenue backlog assumes timing of revenue recognition that may vary from actual results.

Pareteum Investor Relations Contact:
Ted O’Donnell
Chief Financial Officer
(212) 984-1096
InvestorRelations@pareteum.com

Hayden IR
(917) 658-7878

Tuesday, December 26th, 2017 Uncategorized Comments Off on $TEUM Adds Blockchain Settlement for Cryptocurrency to Its Global Cloud Platform

$IGC Up Almost 200%, As Blockchain Added to Cannabis Pharma Platform

Both cannabis and blockchain technology stocks have been on the rise in the year 2017 and are still growing. Just recently, India Globalization Capital Inc. (NYSE:IGC) announced that it will be adding blockchain to its current cannabis pharma platform. At the time of reporting, the stock is up 240.5% and is selling at $1.26 a share.

It will continue to develop methods to utilize blockchain technology in certain areas of the company such as product identification assurance and leveraging its technology team and healthcare experts. The Maryland-based company has two forms of business: a cannabis pharma business and a legacy infrastructure business.

India Globalization Capital has four proprietary cannabis-based products. Hyalolex is a cannabis-based formula used to aid Alzheimer’s disease. The company has the launching of this product to patients set in early 2018. Tetrahydrocannabinol, the psychoactive cannabinoid found within the marijuana plant, is used with a combination of other formulas to slow the buildup of plaque in the brain.

Hyalolex is expected to move though FDA registered preclinical and clinical trials in 2018, at the same time the company expects to license its formulation simultaneously for distribution. IGC will be focusing on cannabis dispensaries within the U.S, focusing its treatment as complementary and alternative medicine for the disease.

The pivot to use blockchain technology comes from IGC’s need to fix the issue of under and over-labeling of cannabidiol products that are sold online. According to a recent study in Jama, almost 70 percent of all cannabidiol products that are sold online are mislabeled.

CEO of India Globalization Capital, Ram Mukunda, said:

“As we work to develop blockchain in the rollout of Hyalolex, our goal would be to establish a universal cannabis platform applicable to solving multiple industry challenges facing dispensaries and consumers. This would include addressing issues such as transactional difficulties, inadequate product labeling, product identification assurance and product origin assurance.”

With legalization currently in 30 states medicinally and 7 of those states recreational, cannabis stocks will continue to rise as it becomes more widely adopted. In additional, Blockchain technology is being adopted worldwide and is now implemented in various sectors to streamline the current systems that are in place.

Featured Image: NASDAQ

Tuesday, December 26th, 2017 Uncategorized Comments Off on $IGC Up Almost 200%, As Blockchain Added to Cannabis Pharma Platform

$RXDX & $RHHBY Reach Definitive Merger Agreement

SAN DIEGO

  • Roche to acquire Ignyta for US$ 27.00 per share
  • Ignyta’s investigational medicine entrectinib, a selective CNS-active tyrosine-kinase inhibitor being developed for tumours that harbor ROS1 or NTRK fusions, to expand Roche’s portfolio of oncology medicines

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 1.7 billion on a fully diluted basis. This price represents a premium of 74% to Ignyta’s closing price on 21 December 2017 and a premium of 71% and 89% to Ignyta’s 30-day and 90-day volume weighted average share price on 21 December 2017, respectively. The merger agreement has been unanimously approved by the boards of Ignyta and Roche.

Under the terms of the merger agreement, Roche will promptly commence a tender offer, to acquire all outstanding shares of Ignyta common stock, and Ignyta will file a recommendation statement containing the unanimous recommendation of the Ignyta board that Ignyta’s shareholders tender their shares to Roche.

Ignyta, based in San Diego, California, is focused on precision medicine in oncology aiming to test, identify, and treat patients with cancers harbouring specific rare mutations.

Ignyta’s lead molecule entrectinib is an orally bioavailable, CNS-active tyrosine kinase inhibitor being developed for tumours that harbor ROS1 or NTRK fusions. An ongoing pivotal phase 2 clinical trial will support, if successful, dual NDA submissions. Entrectinib targets tumours with one of two genetically defined gene rearrangements: ROS1 fusions in non-small cell lung cancer (NSCLC), and NTRK fusions across a broad range of solid tumours.

In the recently announced interim data including patients from the STARTRK-2 trial, in patients with ROS1 fusion-positive advanced NSCLC, entrectinib demonstrated a 78 percent (25 out of 32; by Investigator) and 69 percent (22 out of 32; by blinded independent central review, BICR) confirmed objective response rate (ORR). Entrectinib also showed a median duration of response of 28.6 months and median progression free survival of 29.6 months in this population, with 53 percent of patients remaining on study. Moreover, entrectinib showed 83 percent (5 out of 6 by BICR) confirmed intracranial ORR in patients with measurable brain metastases. Safety was consistent with previous studies of entrectinib. With over 200 patients treated at the recommended phase 2 dose, most adverse events (AEs) were Grade 1-2 and reversible, and only 3 percent of patients discontinued from the study due to treatment-related AEs. The program is tracking towards dual NDA submissions in NTRK tumour-agnostic and ROS1 NSCLC, if supported by clinical data, with an anticipated US commercial launch in both indications thereafter.

Commenting on the transaction, Daniel O’Day, CEO Roche Pharmaceuticals, said, “Cancer is a highly complex disease and many patients suffer from mutations which are difficult to detect and treat. The agreement with Ignyta builds on Roche’s strategy of fitting treatments to patients and will allow Roche to broaden and strengthen its oncology portfolio globally.”

Ignyta will continue its operations in San Diego and be responsible for the ongoing pivotal study of entrectinib to ensure this important medicine reaches patients without delay. Commenting on the transaction, Ignyta’s Chairman, CEO, and Co-Founder, Jonathan E. Lim, said, “Ignyta has been singularly focused on developing precisely targeted therapeutics guided by diagnostics for patients with rare cancers. We are excited that Roche, the global leader in both oncology and personalised healthcare, recognises this powerful approach and shares our passion for advancing entrectinib for the benefit of patients.”

Terms of the agreement

Under the terms of the merger agreement, Roche will promptly commence a tender offer to acquire all of the outstanding shares of Ignyta’s common stock at a price of US$ 27.00 per share in cash. The closing of the tender offer will be subject to a majority of Ignyta’s outstanding shares being tendered in the tender offer. In addition, the transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions.

Following completion of the tender offer, Roche will acquire all remaining shares at the same price of US$ 27.00 per share through a second step merger. The closing of the transaction is expected to take place in the first half of 2018.

Citi is acting as financial advisor to Roche and Sidley Austin LLP is acting as legal counsel to Roche. BofA Merrill Lynch and J.P. Morgan Securities LLC are acting as financial advisors to Ignyta and Latham & Watkins LLP is acting as legal counsel to Ignyta.

About entrectinib

Entrectinib is an investigational, CNS-active, potent, and selective small molecule tyrosine kinase inhibitor of the NTRK (neurotropic tropomyosin receptor kinase) family of tyrosine kinase receptors (TRKA, TRKB and TRKC) and ROS1 proteins, which is in a Phase 2 clinical study in molecularly defined patient populations for the treatment of solid tumours. Entrectinib has been granted PRIME designation by EMA and Breakthrough Therapy Designation by FDA.

About Ignyta

At Ignyta, we work tirelessly on behalf of patients with cancer to offer potentially life-saving, precisely targeted therapeutics (Rx) guided by diagnostic (Dx) tests. Our integrated Rx/Dx strategy allows us to enter uncharted territory, illuminating the molecular and immunological drivers of cancer and quickly advancing treatments to address them. This approach embraces even those patients with rare cancers, who have the highest unmet need and who may otherwise not have access to effective treatment options. With our pipeline of potentially first-in-class or best-in-class precision medicines, we are pursuing the ultimate goal of not just shrinking tumors, but eradicating cancer relapse and recurrence in precisely defined patient populations.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders.

Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

IMPORTANT ADDITIONAL INFORMATION AND WHERE TO FIND IT

THE TENDER OFFER FOR THE OUTSTANDING COMMON STOCK OF IGNYTA HAS NOT BEEN COMMENCED. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO PURCHASE OR A SOLICITATION OF AN OFFER TO SELL IGNYTA COMMON STOCK. THE SOLICITATION AND OFFER TO BUY IGNYTA COMMON STOCK WILL ONLY BE MADE PURSUANT TO AN OFFER TO PURCHASE AND RELATED MATERIALS. AT THE TIME THE OFFER IS COMMENCED, ROCHE AND ITS ACQUISITION SUBSIDIARY, WILL FILE A TENDER OFFER STATEMENT ON SCHEDULE TO WITH THE SEC AND THEREAFTER, IGNYTA WILL FILE A SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WITH RESPECT TO THE OFFER. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) CAREFULLY WHEN THEY BECOME AVAILABLE SINCE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE OFFER. THE OFFER TO PURCHASE, SOLICITATION/RECOMMENDATION STATEMENT AND RELATED MATERIALS WILL BE FILED WITH THE SEC, AND INVESTORS AND SECURITY HOLDERS MAY OBTAIN A FREE COPY OF THESE MATERIALS (WHEN AVAILABLE) AND OTHER DOCUMENTS FILED BY ROCHE AND IGNYTA WITH THE SEC AT THE WEBSITE MAINTAINED BY THE SEC AT WWW.SEC.GOV. INVESTORS AND SECURITY HOLDERS MAY ALSO OBTAIN FREE COPIES OF THE SOLICITATION/RECOMMENDATION STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC BY IGNYTA AT WWW.IGNYTA.COM

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

THIS ANNOUNCEMENT CONTAINS FORWARD-LOOKING STATEMENTS ABOUT IGNYTA AS THAT TERM IS DEFINED IN SECTION 27A OF THE SECURITIES ACT OF 1933 AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934. SOME OF THE STATEMENTS CONTAINED IN THIS ANNOUNCEMENT ARE FORWARD-LOOKING STATEMENTS, INCLUDING STATEMENTS REGARDING, AMONG OTHER THINGS, THE CLINICAL AND/OR NON-CLINICAL DATA OR PLANS UNDERLYING IGNYTA’S ENTRECTINIB PROGRAM, REFERENCES TO THE DEVELOPMENT OF, AND POTENTIAL TIMING OF REGULATORY SUBMISSIONS AND COMMERCIALIZATION FOR ENTRECTINIB, AND THE EXPECTED CONSUMMATION OF THE TRANSACTION, ALL OF WHICH INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES, INCLUDING, THE SATISFACTION OF CLOSING CONDITIONS FOR THE TRANSACTION, SUCH AS REGULATORY APPROVAL, THE TENDER OF A MAJORITY OF THE OUTSTANDING SHARES OF COMMON STOCK OF IGNYTA, THE POSSIBILITY THAT THE TRANSACTION WILL NOT BE COMPLETED, AND OTHER RISKS AND UNCERTAINTIES DISCUSSED IN IGNYTA’S PUBLIC FILINGS WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (THE “SEC”), INCLUDING THE “RISK FACTORS” SECTIONS OF IGNYTA’S ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2016 AND SUBSEQUENT QUARTERLY REPORTS ON FORM 10-Q, AS WELL AS THE TENDER OFFER DOCUMENTS TO BE FILED BY ROCHE AND ITS ACQUISITION SUBSIDIARY AND THE SOLICITATION/RECOMMENDATION TO BE FILED BY IGNYTA. THESE STATEMENTS ARE BASED ON CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS, AND INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS THAT MAY CAUSE RESULTS, LEVELS OF ACTIVITY, PERFORMANCE OR ACHIEVEMENTS TO BE MATERIALLY DIFFERENT FROM ANY FUTURE STATEMENTS. IF UNDERLYING ASSUMPTIONS PROVE INACCURATE OR UNKNOWN RISKS OR UNCERTAINTIES MATERIALIZE, ACTUAL RESULTS AND THE TIMING OF EVENTS MAY DIFFER MATERIALLY FROM THE RESULTS AND/OR TIMING DISCUSSED IN THE FORWARD-LOOKING STATEMENTS, AND YOU SHOULD NOT PLACE UNDUE RELIANCE ON THESE STATEMENTS. ROCHE AND IGNYTA DISCLAIM ANY INTENT OR OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENTS AS A RESULT OF DEVELOPMENTS OCCURRING AFTER THE PERIOD COVERED BY THIS REPORT OR OTHERWISE.

 

Ignyta, Inc.
Jacob Chacko, M.D.
CFO
858-255-5959
jc@ignyta.com

Friday, December 22nd, 2017 Uncategorized Comments Off on $RXDX & $RHHBY Reach Definitive Merger Agreement

$SGLB Awarded Contract with Laser Zentrum

SANTA FE, N.M., Dec. 22, 2017 — Sigma Labs, Inc. (NASDAQ:SGLB) (“Sigma Labs” or the “Company”), a provider of quality assurance software under the PrintRite3D® brand, today announced that it has received a contract from Laser Zentrum Nord (LZN) GmbH, a leading Additive Manufacturing (AM) technology and research innovator located in Hamburg, Germany for PrintRite 3D INSPECT®.  Terms of the contract have not been disclosed.

The two companies have also agreed to actively collaborate to certify Sigma’s IPQA® methodology and solutions for serial production 3D printing in the aerospace industry. The PrintRite3D® system will be installed onto a SLM Solutions selective laser melting machine located at Laser Zentrum Nord GmbH in Hamburg, Germany.

“Advancements of 3D metal printing into production have been hampered by the inability to identify, monitor and mitigate defects during the printing process,” said John Rice, Chief Executive Officer of Sigma Labs. “We’re excited to work with Laser Zentrum Nord GmbH on the in- process dynamic behaviors that cause defects and to demonstrate and document how our PrintRite3D IPQA® software addresses and solve these problems. This contract further validates Sigma Labs’ position as a leader in third party, platform independent quality assurance for the metal additive manufacturing industry.”

This instillation will add an additional machine platform to Sigma Labs’ successes for the deployment of Sigma Labs’ PrintRite 3D® quality assurance technology.

About Sigma Labs
Sigma Labs, Inc. is a provider of quality assurance software under the PrintRite3D® brand and a developer of advanced, in-process, non-destructive quality assurance software for commercial firms worldwide seeking productive solutions for advanced manufacturing. For more information please visit us at www.sigmalabsinc.com.

About Laser Zentrum Nord GmbH

The Laser Zentrum Nord GmbH, founded in 2009, pursues the goal of decisively promoting knowledge and technology transfer from basic research to industrial application. Their objective is to decisively improve, facilitate and accelerate the transfer of knowledge and technology from basic research to industrial application. The LZN serves as a link between basic research and application in an effort to strengthen company’s completive position within their respective industries.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K (including but not limited to the discussion under “Risk Factors” therein) filed with the SEC on March 31, 2017 and which may be viewed at http://www.sec.gov.

Investor Relations Contact:
Bret Shapiro
Managing Director
CORE IR
561-479-8566
brets@coreir.com

Friday, December 22nd, 2017 Uncategorized Comments Off on $SGLB Awarded Contract with Laser Zentrum

$CIIX NetworkNewsAudio Covers Recent Interview on Top-Rated Cryptocurrency Podcast

NEW YORK, Dec. 22, 2017 — via NetworkNewsWire — NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions for business, today announces the audio version of the press release titled “Top-Rated Cryptocurrency Podcast, ‘Bad Crypto Podcast’ Features Interview with ChineseInvestors.com, Inc.’s CEO, Warren Wang” recently issued by ChineseInvestors.com, Inc. (OTC:CIIX).

To hear the NetworkNewsAudio version, visit http://nnw.fm/Oz7CQ

To read the original press release, visit http://nnw.fm/iM8jR

About ChineseInvestors, Inc.

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products.

For more information, visit ChineseInvestors.com

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a complimentary service of NetworkNewsWire. For more information, visit: https://www.networknewswire.com/networknewsaudio/.

NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today’s markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Friday, December 22nd, 2017 Uncategorized Comments Off on $CIIX NetworkNewsAudio Covers Recent Interview on Top-Rated Cryptocurrency Podcast

$VSQTF NetworkNewsWire Announces Publication on Diverse Applications of Blockchain

NEW YORK, Dec. 22, 2017 — via NetworkNewsWire — NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Victory Square Technologies, Inc. (CSE:VST) (OTC:VSQTF) (FWB:6F6), a client of NNW and venture builder that creates, funds and empowers entrepreneurs predominantly focused on blockchain technology, virtual reality, artificial intelligence, personalized health, gaming and film.

The publication titled, “Blockchain Technology’s Usefulness Promotes Innovation for Wide Range of Industries,” reviews how several companies are leveraging their individual capabilities to take advantage of blockchain applications.

To view the full publication, visit: https://www.networknewswire.com/blockchain-technologys-usefulness-promotes-innovation-wide-range-industries/

Victory Square Technologies, Inc.’s (CSE:VST) (OTC:VSQTF) (FWB:6F6) core mission is to fund and empower entrepreneurs who display promise in a variety of fields, including the burgeoning blockchain technology, as part of its goal to promote innovation on a global scale. The company helps entrepreneurs grow internationally by making distribution partners, mentorship networks, creative workspaces and other resources available to them.

Victory Square sees blockchain as the next major platform for innovation, standing out as a technology that has the potential to change the way businesses and a wide array of societies connect with each other. Pivoting from this early-recognized potential, Victory Square began its ascent in blockchain based on management’s ability to recognize key investment opportunities with plenty of room to grow.

Victory Square is looking to take advantage of another market opportunity in software defined wide area networking (SD-WAN) through its recently announced intent to invest in SD-WAN blockchain company Multapplied Networks, Inc. (“MNI”). Focused on utilizing its proprietary software to establish a global blockchain-enabled networking economy, MNI delivers its technology through a portfolio of global channel partners in North America, Europe, Asia, Africa and Australia, and is on pace to top revenues of $1.2 million in 2017. Revenues for 2018 are projected to exceed CAD$3 million.

About Victory Square Technologies Inc.

Victory Square is a venture builder that creates, funds and empowers entrepreneurs predominantly focused on Blockchain Technology, Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film. As a technology incubator, Victory Square invests in game-changing entrepreneurs who are provided access to education programs, global mentorship networks, distribution partners, creative workspaces, resources and other forms of operational support to help them scale internationally. For more information, visit www.VictorySquare.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Friday, December 22nd, 2017 Uncategorized Comments Off on $VSQTF NetworkNewsWire Announces Publication on Diverse Applications of Blockchain

$NXTD Announces $7,000,000 Registered Direct Offering

MELBOURNE, Fla., Dec. 21, 2017 — NXT-ID, INC. (NASDAQ:NXTD), a security technology company, today announced that it has entered into definitive agreements with certain institutional investors to purchase an aggregate of approximately $7,000,000 of shares of common stock in a registered direct offering. The common stock will be priced at $4.00 per share. Upon closing, the Company anticipates that it will issue a total of approximately 1,750,000 registered common shares. The Company intends to use the proceeds for further debt reduction, to fund its Crypto Currency exchange product development and for general corporate purposes.

The offering is expected to yield gross proceeds of $7,000,000, before deducting placement agent fees and other estimated offering expenses.  The closing of the offering is expected to take place on or about December 26, 2017, subject to the satisfaction of customary closing conditions.

Aegis Capital Corp. is acting as the lead placement agent in connection with this offering. Maxim Group LLC is acting as a co-placement agent in connection with this offering.

This offering is being made pursuant to an effective shelf registration statement (No. 333-203637) previously filed with and declared effective by the U.S. Securities and Exchange Commission (the “SEC”).  A prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.  Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from Aegis Capital Corp., 810 7th Avenue, 18th Floor, New York, NY 10019 or via telephone at 212-813-1010 or email: prospectus@aegiscap.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About NXT- ID Inc. – Mobile Security for a Mobile World: (NXTD)
NXT-ID, Inc. (NASDAQ:NXTD) provides a comprehensive platform of technology products and services that enable the Internet of Things (IoT). With extensive experience in access control, biometric and behavior-metric identity verification, security and privacy, encryption and data protection, payments, miniaturization and sensor technologies, NXT-ID develops and markets groundbreaking solutions for payment and IoT applications. Its industry-leading technology products and solutions include MobileBio®, a suite of biometric solutions that secure consumers’ mobile platforms, the Wocket™, a next-generation smart wallet and the Flye, a digital credit card developed in collaboration with WorldVentures.

NXT-ID includes three mobile and IoT-related subsidiaries: LogicMark, LLC, a manufacturer and distributor of non-monitored and monitored personal emergency response systems (“PERS”) sold through dealers/distributors and the United States Department of Veterans Affairs; Fit Pay, Inc., a proprietary technology platform that delivers end-to-end solutions to device manufacturers for contactless payment capabilities, credential management, authentication and other secure services within the IoT ecosystem, and 3D-ID LLC, which is engaged in biometric identification and authentication. Learn more about NXT-ID at www.nxt-id.com.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties.  These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target”, “intend” and “expect” and similar expressions, as they relate to NXT-ID, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

NXT- ID Inc Contact:

Corporate info: info@nxt-id.com

Investors:
investors@nxt-id.com

Media:
D. Van Zant
800 665-0411
press@nxt-id.com

Thursday, December 21st, 2017 Uncategorized Comments Off on $NXTD Announces $7,000,000 Registered Direct Offering

$LTEA to Rebrand as “Long Blockchain Corp.”

Corporate Focus to Shift Towards Opportunities Strategic to Blockchain Technologies

Farmingdale, NY , Dec. 21, 2017  — Long Island Iced Tea Corp. (NasdaqCM: LTEA) (the “Company”), today announced that the parent company is shifting its primary corporate focus towards the exploration of and investment in opportunities that leverage the benefits of blockchain technology. In connection with the shift in strategic direction, the Company has approved changing its name from “Long Island Iced Tea Corp.” to “Long Blockchain Corp.” and has reserved the web domain www.longblockchain.com. The Company intends to request Nasdaq to change its trading symbol in connection with the name change. The Company will continue to operate Long Island Brand Beverages, LLC as a wholly-owned subsidiary and maintain the focus of this business on the ready-to-drink segment of the beverage industry, specifically, premium, ‘better-for-you’ brands marketed at an affordable price.

In conjunction with the shift in business strategy, the Company has submitted a request to the Securities and Exchange Commission to withdraw its previously filed S-1 registration statement relating to a proposed underwritten public offering, which was filed on November 11, 2017.

Focus in Blockchain

Blockchain acts as a public, decentralized ledger. This ledger provides a single, unified source of data, creating a clearer audit trail and consistency across parties.  The Company believes that emerging blockchain technologies are creating a fundamental paradigm shift across the global marketplace, with far reaching applications across all industries from financial services (smart settlements) to consumer packaged goods (supply chain verification) to healthcare (electronic medical records).

The Company is already in the preliminary stages of evaluating specific opportunities involving blockchain technology. The discussions are only in the preliminary stages but indicate the areas of focus for the Company. These opportunities include potential partnerships, investments or acquisitions involving:

  • A blockchain software developer building blockchain infrastructure for the financial services industry
  • A London-based FCA regulated, institutional provider of FX services that is building multiple blockchain and digital crypto currency technology solutions for global financial markets
  • A new smart contract platform for building decentralized applications that provides scalability beyond currently available options

However, the Company does not have an agreement with any of these entities for a transaction and there is no assurance that a definitive agreement with these, or any other entity, will be entered into or ultimately consummated.

Philip Thomas, Chief Executive Officer of the Company, commented, “We view advances in blockchain technology as a once-in-a-generation opportunity, and have made the decision to pivot our business strategy in order to pursue opportunities in this evolving industry. We are committed to enhancing shareholder value and believe that our new focus is the best path towards this goal. We will, in the coming weeks and months, be taking a series of steps related to our efforts to assemble a world-class team of industry professionals to help us realize this vision. We are pursuing our new direction in a thoughtful and deliberate manner.”

Long Island Iced Tea®

The Company will continue to leverage its ownership of the iconic Long Island Iced Tea® brand name and its existing beverage portfolio, and remains committed to improving the cash flow profile and efficiency of the beverage business through recently adopted operating initiatives.

“I am incredibly proud of what we have accomplished in the beverage industry and we are committed to growing our business both on a national and international scale,” Mr. Thomas continued.  “I want to assure our beverage industry customers, suppliers, and partners of our continuing support of the Long Island Iced Tea portfolio of beverages. Your support over the years has helped to drive our growth and elevate our brand, and we remain committed to maintaining and fostering these relationships.”

About Long Island Iced Tea Corp.

Long Island Iced Tea Corp. is now focused on developing and investing in globally scalable blockchain technology solutions. It is dedicated to becoming a significant participant in the evolution of blockchain technology that creates long term value for its shareholders and the global community by investing in and developing businesses that are “on-chain”. Blockchain technology is fundamentally changing the way people and businesses transact, and the Company will strive to be at the forefront of this dynamic industry, actively pursuing opportunities. Its wholly-owned subsidiary Long Island Brand Beverages, LLC operates in the non-alcohol ready-to-drink segment of the beverage industry under its flagship brand ‘The Original Long Island Brand Iced Tea®’.

Forward Looking Statements 

This press release includes statements of the Company’s expectations, intentions, plans and beliefs that constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to come within the safe harbor protection provided by those sections. These statements, which involve risks and uncertainties, relate to the discussion of the Company’s business strategies and its expectations concerning future operations, margins, sales, new products and brands, potential joint ventures, potential acquisitions, expenses, profitability, liquidity and capital resources and to analyses and other information that are based on forecasts of future results and estimates of amounts not yet determinable. These statements include any statement that does not directly relate to a historical or current fact. You can also identify these and other forward-looking statements by the use of such words as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “thinks,” “estimates,” “seeks,” “predicts,” “could,” “projects,” “potential” and other similar terms and phrases, including references to assumptions. These forward looking statements are made based on expectations and beliefs concerning future events affecting the Company and are subject to uncertainties, risks and factors relating to its operations and business environments, all of which are difficult to predict and many of which are beyond its control, that could cause its actual results to differ materially from those matters expressed or implied by these forward looking statements. These risks include the Company’s history of losses and expectation of further losses, its ability to expand its operations into blockchain technologies, its ability to develop or acquire new brands, the success of its marketing activities, the effect of competition in its industry and economic and political conditions generally, including the current economic environment and markets. More information about these and other factors are described in the reports the Company files with the Securities and Exchange Commission, including but not limited to the discussions contained under the caption “Risk Factors.” When considering these forward looking statements, you should keep in mind the cautionary statements in this press release and the reports the Company files with the Securities and Exchange Commission. New risks and uncertainties arise from time to time, and the Company cannot predict those events or how they may affect it. The Company assumes no obligation to update any forward looking statements after the date of this press release as a result of new information, future events or developments, except as required by the federal securities laws.

Contacts:

For Investors

Philip Thomas

Long Island Iced Tea Corp.

1-855-542-2832

info@longislandteas.com
Thursday, December 21st, 2017 Uncategorized Comments Off on $LTEA to Rebrand as “Long Blockchain Corp.”

$DJACF and Tokyo Smoke announce merger and strategic investment from Aphria Inc.

Canada NewsWire

KELOWNA, BC and TORONTO, Dec. 21, 2017

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE OR
FOR DISSEMINATION IN THE UNITED STATES

Merger creates Canada’s first retail- & brand-focused cannabis producer 

Two Canadian cannabis lifestyle brands join forces in a transformational transaction, bringing together industry leading management teams, British Columbia curated handcrafted cannabis production, a portfolio of visionary brands and a growing nationwide retail footprint.

Provides the first public markets investment opportunity focused on cannabis retail and brand; high-margin verticals with significant growth potential.

A strategic financing of $12.5 million led by Aphria Inc. will bolster the combined company’s cash position to approximately $31 million, which the company plans to invest in scaling up production capacity, expanding its retail footprint and further building-out its portfolio of cannabis brands.

KELOWNA, BC and TORONTO, Dec. 21, 2017  – DOJA Cannabis Company Limited (“DOJA“) (CSE:DOJA) and TS Brandco Holdings Inc. (“Tokyo Smoke“) are pleased to announce that they have entered into a binding Letter of Intent (“LOI“) dated December 20, 2017, setting out the terms pursuant to which DOJA proposes to acquire (the “Merger“) all of the issued and outstanding shares in the capital of Tokyo Smoke (the “Tokyo Smoke Shares“). The Merger will create a uniquely positioned cannabis company combining a best-in-class craft cannabis producer with an award-winning lifestyle brand and retail-focused cannabis company. It is anticipated that the combined company resulting from the Merger will use the name “Hiku Brands Company Ltd.” (“Hiku” or the “Company“) to refer to the brand house containing premium cannabis brands DOJA, Tokyo Smoke, and Van der Pop.

Concurrently, DOJA is pleased to announce it has entered into a binding agreement with Aphria Inc. (“Aphria“) (TSX:APH and US OTC: APHQF) pursuant to which Aphria has committed to make a $10 million strategic equity investment into Hiku. Additionally, the parties have agreed on the terms of a supply agreement, to be entered into in connection with the Merger (the “Supply Agreement“), to secure cannabis concentrate supply for Hiku’s premium brand portfolio.

Upon completion of the Merger, the Company will have a robust cash position of approximately $31 million, which it plans to invest in expanding its cannabis production capacity, growing its retail footprint, and adding select brands to its portfolio through highly strategic and complementary acquisitions.

DOJA’s Board of Directors and Tokyo Smoke’s Board of Directors have approved the Merger.

Highlights of the Transformational Transaction

Key investment highlights of the Company include:

  • Creation of the first retail-focused, craft cannabis producer with a portfolio of leading lifestyle cannabis brands: Hiku will be differentiated as the only Canadian craft cannabis producer with significant national retail presence and a growing portfolio of premium cannabis lifestyle brands including DOJA, Tokyo Smoke, and Van der Pop, appealing to a wide variety of consumers across Canada and globally.
  • Well positioned to capitalize on Canada’s recreational cannabis market through retail: Hiku has multiple highly recognizable brands and strategies in place to operate retail cannabis stores across various provinces. Vertically integrated operations position Hiku to offer exclusive products in Hiku-owned stores and achieve superior margins versus peers.
  • Licensed producer under the Access to Cannabis for Medical Purposes Regulations (ACMPR): 7,100 square foot production facility licensed by Health Canada. DOJA’s second facility, a 22,580 sq ft warehouse, will house the FUTURE LAB. The FUTURE LAB is targeting its Phase 1 completion by Q2 2018 and once the facility is fully built-out utilizing an industry leading multi-tier system powered by LED lighting provided by Fluence BioEngineering, DOJA’s annual production capacity is expected to be in excess of 5,000 kgs.
  • Retail locations from Eastern to Western Canada, with plans to expand: Hiku will have seven operational, legal cannabis accessory stores with locations across Canada (Ontario, Alberta and British Columbia), representing an unprecedented platform to build brand awareness and reach consumers. Hiku will prioritize retail expansion in provinces allowing private cannabis retail and Tokyo Smoke and DOJA will respond to the Government of Manitoba’s Request for Proposals to establish retail cannabis stores throughout the province.
  • Strategic Partnership with Aphria: Aphria’s strategic investment into Hiku marks Aphria’s first venture into British Columbia’s premium cannabis market. Combined with the Supply Agreement, the partnership with Aphria brings unparalleled experience in cannabis production and ensures secured supply for what is expected to be a supply-constrained market at the onset of legalization.
  • Led by industry leading management and team: Hiku management has breadth and depth of expertise, with a proven track record of building and scaling businesses, including SAXX Underwear and a $100 million+ business at Google. The supporting team brings expertise from the retail, cannabis, finance, design, marketing and creative fields.
  • Well capitalized for local and global growth: Post-Merger, Hiku is expected to have a cash balance of approximately $31 million and to be well positioned to expand within the Canadian market and enter into the emerging global cannabis markets.
  • Enhanced capital markets profile: The combined entity post-financing is anticipated to have a basic market capitalization of approximately $175 million at the transaction price, as well as increased trading liquidity for existing and prospective shareholders.

DOJA operates a cannabis production facility in British Columbia’s Okanagan Valley, and is in the process of building FUTURE LAB, DOJA’s new production facility to be located in Kelowna, British Columbia to support production capacity in excess of 5,000 kg per year. DOJA also operates the Culture Café, a café located on Kelowna’s busiest street serving as a cannabis information centre that generates brand awareness. With the addition of Tokyo Smoke, an award-winning lifestyle brand with six coffee and cannabis accessory shops, Hiku will have a retail presence across Canada with a portfolio of multiple recognized cannabis brands including DOJA, Tokyo Smoke and Van der Pop. The Company’s aggressive growth strategy will be supported by a strong balance sheet, positioning Hiku to be the preeminent craft cannabis brand house in the Canadian adult-use cannabis market.

Trent Kitsch, CEO of DOJA, said, “We have created the leading brand house in Cannabis. Where high quality and design will shape the Cannabis Future. I am confident Hiku will be trusted by consumers to design better customer experiences and products, resulting in greater market share. Tokyo Smoke’s experienced management team has proven its ability to build and acquire respected cannabis brands and create brand awareness in a difficult-to-navigate regulatory environment. We see leveraging those skills and their strong retail operating abilities as highly complementary to our current operations and beneficial to the long-term trajectory of our company. The combination of cannabis production, retail footprint, and a portfolio of cannabis brands gives us the opportunity to realize the significant value of complete vertical integration.”

Alan Gertner, CEO of Tokyo Smoke, added, “DOJA is an incredible organization, team and brand. DOJA’s deeply authentic BC story combined with being one of the only licensed producers that have access to unique genetics through an import license creates a platform to provide customers an unrivaled premium experience. Not to mention, DOJA’s cultivation team has already demonstrated their ability to deliver on all levels of production, including quality, yield and ensuring the plant’s fullest potential is expressed through aroma, flavor and effects. Craft British Columbia approach, top notch branding, and retail will allow Hiku to have a distinctive business; high quality control, high demand and high margin.”

“This strategic investment in and supply agreement with Hiku further bolsters our relationship with Tokyo Smoke and now DOJA, and reaffirms our commitment to expanding our product offering ahead of the recreational market,” said Vic Neufeld, Chief Executive Officer of Aphria. “This transaction has the twofold benefit of providing us access to strong brands, through Tokyo Smoke and DOJA, and craft-cultivated British Columbia bud, through DOJA. Quality product and recognizable consumer brands will be key differentiators for patients and consumers, and we’re looking forward to continuing our work with Hiku to create premium cannabis brands in Canada.”

Benefits to DOJA Shareholders

  • Tokyo Smoke owns two premium cannabis brands in the cannabis industry, Van der Pop and Tokyo Smoke, the recipient of the 2017 Canadian Cannabis Brand of the Year Award
  • Internationally acclaimed and award-winning cannabis accessory stores with locations cross country
  • The addition of a management team with deep relevant experience from Google, Samsung, Bain & Company, Barneys New York, David’s Tea, Lululemon, Kit & Ace, PharmaCan Capital (now Cronos Group), Privateer and Marley’s Natural
  • Completed licensing and supply deals in Canada
  • Strategic investment of $12.5 million led by Aphria and including Uji Capital

Merger Structure and Terms

Under the terms of the Merger, DOJA will acquire all of the outstanding Tokyo Smoke Shares in exchange for shares of DOJA (“DOJA Shares“).

The LOI currently contemplates the parties entering into a definitive agreement (the “Definitive Agreement“) prior to January 15, 2018, and completing the Merger by no later than March 31, 2018, unless otherwise agreed by the parties.

The Merger is subject to requisite regulatory approvals, including the approval of the Canadian Securities Exchange, requisite Tokyo Smoke shareholder approval and standard closing conditions, including the approval of the Definitive Agreement by the boards of the respective companies and completion of due diligence investigations to the satisfaction of each of the parties. The legal structure for the Merger will be confirmed after the parties have considered all applicable tax, securities law, and accounting efficiencies.

Based upon the number of Tokyo Smoke Shares outstanding as at December 21, 2017, if the Merger is completed, DOJA will issue approximately 55.6 million DOJA Shares to the shareholders of Tokyo Smoke in exchange for their Tokyo Smoke Shares.

Strategic Financing

Aphria, along with Uji Capital (collectively the “Strategic Investors“) have entered into binding agreements with DOJA pursuant to which the Strategic Investors will acquire from DOJA, on a non-brokered private placement basis, 8,992,805 subscription receipts (the “Subscription Receipts“) of DOJA at a purchase price of $1.39 per Subscription Receipt, equivalent to DOJA’s five day volume weighted share price, for aggregate gross proceeds of $12.5 million (the “Strategic Financing“).

The Subscription Receipts will be automatically convertible into units of Hiku (the “Units“) upon the satisfaction of certain escrow release conditions, with each Unit comprised of one common share of Hiku (a “Common Share“) and one Common Share Purchase Warrant of Hiku (a “Warrant“). Each Warrant will be exercisable to acquire one common share (a “Warrant Share“) for a period of two years from the closing date of the Merger at an exercise price of $2.10 per Warrant Share. If, following the closing of the Merger, the volume weighted average price of the Common Shares on the Canadian Securities Exchange is equal to or greater than $3.05 for any twenty (20) consecutive trading days, Hiku may, upon providing written notice to the holders of the Warrants, accelerate the expiry date of the Warrants to the date that is 30 days following the date of such written notice.

Closing of the Strategic Financing is subject to the satisfaction of certain closing conditions including, but not limited to, closing of the Merger, the receipt of all necessary approvals, including the approval of the Canadian Securities Exchange.

Management Team
The proposed management team of Hiku has a proven entrepreneurial track record and, collectively, decades of experience in branding, marketing, corporate strategy and retail operations. Trent Kitsch, presently CEO of DOJA, will become President of Hiku while Alan Gertner, presently CEO of Tokyo Smoke, will serve as CEO of Hiku.

Alan Gertner, CEO Hiku
Alan Gertner is most recently the co-founder of Tokyo Smoke, an award winning cannabis brand created in 2014. He built Tokyo Smoke from the ground up into a full scale organization with internationally recognized brands and a cross country network of retail stores. Previously, Alan spent six years at Google, initially on Google’s first Global Business Strategy team, then leading a $100 million+ revenue organization in Asia Pacific. Alan was formerly a Management Consultant at Oliver Wyman in New York and graduated Dean’s list from the Richard Ivey School of Business. He brings more than 15 years of strategy, marketing and executive experience to the new management team. He was named one of the Most Influential People in Toronto in 2017 as recognition for his leadership in the Cannabis industry.

Trent Kitsch, President Hiku
Trent founded SAXX Underwear Co. in 2007 and successfully built SAXX into a globally recognizable brand and the fastest growing underwear brand in North America before exiting the business in 2016. In 2013 Trent and his wife Ria founded Kitsch Wines in the Okanagan Valley which has quickly grown into an award-winning winery with a unique millennial following. The ACMPR application and conception of DOJA started in 2013 and has authentically represented cannabis culture and positioned DOJA as a leading premium cannabis lifestyle brand. Trent is an MBA graduate of the Richard Ivey School of Business with a major in Entrepreneurship, and recently was selected as one of 10 Ivey Ambassadors for Entrepreneurship.

About DOJA Cannabis Company Limited
DOJA™ is a premium cannabis lifestyle brand growing high-quality handcrafted cannabis flower. DOJA’s wholly owned subsidiary is a licensed producer of cannabis under the ACMPR that has requested its Pre-Sales License Inspection, the last step prior to receiving a license to sell cannabis under the ACMPR. DOJA’s state-of-the-art ACMPR licensed production facility is located in the heart of British Columbia’s picturesque Okanagan Valley. DOJA was founded by the proven entrepreneurial team that started SAXX Underwear®.

About Tokyo Smoke
Founded in 2015 by Alan and Lorne Gertner, Tokyo Smoke is an award-winning cannabis lifestyle brand that brings sophistication and design to the fast-growing industry. With immersive experiences and design-first, non-dispensary retail spaces selling coffee, cannabis accessories and design products, the brand has six locations in Canada, with plans to expand nationwide. Recently named “Brand of the Year” at the Canadian Cannabis Awards, Tokyo Smoke has showcased excellence in brand storytelling, and has developed an international reputation as the go-to destination for engaging content offerings within the industry. With the completion of its Series A and B funding – resulting in approximately $10 million in total raised capital, the acquisition of fellow designer cannabis brand Van der Pop, and by partnering with Aphria Inc. (TSX: APH  and US OTC: APHQF) and WeedMD (TSXV: WMD), Tokyo Smoke continues to be the leading Canadian brand in the cannabis space.

About Hiku
Hiku is focused on handcrafted cannabis production, immersive retail experiences, and building a portfolio of iconic, engaging cannabis lifestyle brands. Hiku is differentiated as the only Canadian craft cannabis producer with a significant national retail footprint and a growing brand house including premium cannabis lifestyle brands DOJA, Tokyo Smoke, and Van der Pop.

Hiku’s wholly owned subsidiary, DOJA Cannabis Ltd., is a federally licensed producer pursuant to the ACMPR, owning two production facilities in the heart of British Columbia’s Okanagan Valley. The company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

For more information, please visit www.hikubrands.com

About Aphria
Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause DOJA’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Forward-looking statements in this document include statements regarding DOJA’s expectations regarding the structure and completion of the Transaction, the terms and quantum of the Strategic Financing, the Supply Agreement, its future cash position and market capitalization, plans to expand its cannabis production capacity, its plans to add select brands to its portfolio through strategic and complementary combinations, its intent to change its name, the composition of the board of directors and management team of the combined Company, the anticipated benefits to DOJA shareholders, regulatory approvals and other statements that are not historical facts.  By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others:

  • that there is no assurance that the parties will obtain the requisite director, shareholder and regulatory approvals for the Transaction;
  • there is no assurance that the Transaction will close on the terms anticipated or at all;
  • following completion of the Transaction, the combined Company may require additional financing from time to time in order to continue its operations; financing may not be available when needed or on terms and conditions acceptable to the combined Company;
  • new laws or regulations could adversely affect the combined Company’s business and results of operations;
  • the combined Company or their suppliers may experience crop failures which could adversely affect the combined Company’s business and results of operations;
  • fluctuations in currency and interest rates could have a negative impact on the combined Company’s financial results, and
  • stock markets have experienced volatility that often has been unrelated to the performance of companies. These fluctuations may adversely affect the price of the combined Company’s securities regardless of its operating performance.

When relying on the DOJA’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and risks and other uncertainties and potential events. DOJA has assumed that the material factors referred to in the previous paragraphs will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. DOJA undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS NEWS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS NEWS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.

SOURCE DOJA Cannabis Company Limited

Thursday, December 21st, 2017 Uncategorized Comments Off on $DJACF and Tokyo Smoke announce merger and strategic investment from Aphria Inc.

$VSQTF Adds Blockchain Pioneer, Bluzelle CEO Pavel Bains as Strategic Advisor

VST also invited to participate in Bluzelle’s early-contributors’ round on upcoming token sale

VANCOUVER, British Columbia, Dec. 21, 2017 — Victory Square Technologies Inc. (“Victory Square” or the “Company”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) has added the blockchain and cryptocurrency expertise of Pavel Bains, Chief Executive Officer of Bluzelle Platform Pte. Ltd. (“Bluzelle”), as a Strategic Advisor and has been invited to participate in Bluzelle’s early contributors’ round for its upcoming token sale.  The Company has received and will be purchasing a $500,000 allocation of Bluzelle tokens (BLZ), with an additional 25% of bonus tokens provided to Victory Square for being an early-contributor.

“Victory Square exists to enable the next generation of entrepreneurs to experiment, iterate and reinvent both themselves and their businesses to provide innovative solutions to problems with a global reach,” said Shafin Diamond Tejani, CEO of Victory Square. “Pavel is an exemplary individual who has a wealth of experience to impart on other entrepreneurs and we look forward to having him help shape the trajectory of many of the companies in our blockchain portfolio.”

Bluzelle is a decentralized database service where users are able to rent out their computer storage space and be compensated with a cryptocurrency token. Decentralized app developers spend these same tokens to have their decentralized app’s data stored and managed. Decentralized database services have the potential to provide more scalable, secure and affordable storage solutions than current centralized alternatives and represent a huge opportunity with database services estimated to reach over $14 billion by 2019 (source: https://www.marketsandmarkets.com/PressReleases/cloud-database-as-a-service-dbaas.asp).

“As a Canadian entrepreneur now operating abroad, it gives me great pleasure to continue to be able to contribute to the startup community back home,” said Bains. “This advisory role with Victory Square will provide me with the opportunity to help mold some of the most promising blockchain enterprises to come out of Canada. As a futurist and entrepreneur, I relish the opportunity to align myself with organizations like Victory Square that value innovation and the enablement of entrepreneurs solving problems on a global scale.”

Bluzelle was recently awarded Technology Pioneer status by the World Economic Forum, an award previously won by companies like Google, Mozilla, Kickstarter and Twitter. The company has the backing of established thought leaders in the global blockchain community such as Ryan Fugger, original creator of Ripple, and Alex Leverington, a core development member of Ethereum.

“We’re extremely confident in the Bluzelle management team after having worked with Pavel Bains for the past two years,” added Victory Square CEO Tejani. “We’ve watched them build trusted enterprise-grade blockchain technology for businesses such as Microsoft, KPMG, HSBC, Zagbank, and Temenos. Victory Square sees this as a strategic opportunity as Bluzelle’s technology can be used by many of our portfolio companies.

As a Strategic Advisor, Bluzelle CEO Bains will assist in identifying and collaborating with the next generation of entrepreneurs developing blockchain companies. He will also be working with Victory Square portfolio company Blockchain Assembly to provide advisory services over technology architecture and development, as well as guidance on Initial Coin Offerings (ICO) & Token Generation Events (TGE).

Bains is a well-recognized thought leader in blockchain and fintech, having been a speaker at conferences including the World Blockchain Forum and BlockShow Asia and appeared on CNBC’s Squawk Box. He is also a regular contributor to technology publications such as Forbes, Huffington Post, and CoinTelegraph. A serial entrepreneur, Bains was also the co-founder of Storypanda, a digital book platform that published critically acclaimed titles by the world’s best independent authors.

For further information about the Company, please contact:
Howard Blank, Director
Email: ir@victorysquare.com
Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.
Victory Square is a venture builder that creates, funds and empowers entrepreneurs predominantly focused on Blockchain Technology, Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film. As a technology incubator, Victory Square invests in game-changing entrepreneurs who are provided access to education programs, global mentorship networks, distribution partners, creative workspaces, resources and other forms of operational support to help them scale internationally. For more information, please visit www.victorysquare.com.

ABOUT THE CANADIAN SECURITIES EXCHANGE (CSE)
The Canadian Securities Exchange, or CSE, is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004, the CSE began operations in 2003 to provide a modern and efficient alternative for companies looking to access the Canadian public capital markets. The CSE has not reviewed, nor approved or disapproved the content of this news release.

FORWARD-LOOKING INFORMATION
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Victory Square. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square, including future plans. Although Victory Square believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Victory Square can give no assurance that they will prove to be correct. Forward- looking statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Thursday, December 21st, 2017 Uncategorized Comments Off on $VSQTF Adds Blockchain Pioneer, Bluzelle CEO Pavel Bains as Strategic Advisor

$EMMBF and Dosecann Inc. Sign Licensing Deal to Develop Dosage-Controlled Formulations

Agreement Paves Way for More Accessible Dosing and More Consistent Delivery Systems

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

TORONTO, Dec. 21, 201 — Emblem Corp. (TSX-V:EMC) (EMC.WT) (“Emblem” or the “Company”), has entered into a licensing agreement with Dosecann Inc. (“Dosecann”) pursuant to which Dosecann will begin developing a range of cannabinoid dosage formulations designed to ensure patients are better able to titrate and administer each dose the exact same way.

The two companies will begin work immediately on the development of a cannabis-oil oral spray dosage form, followed by the development of two separate dose-controlled vaporizers.

“We are very excited about our relationship with Dosecann,” says Nick Dean, President and CEO of Emblem Corp. “We are focused on and committed to investing in pharmaceutical research and development and bringing more medically-focused products to market. We expect that these dosage-controlled products will have a major impact on the Canadian medical cannabis market and we’re looking forward to further collaborations with Dosecann to bring other value-added cannabis based metered-dosage forms to the market.”

The licensing agreement involves a number of research related aspects including research into pre-clinical formulations, clinical development, as well as regulatory approval, manufacturing and the commercialization and distribution of a range of cannabinoid dosage forms.

The agreement provides for both Emblem and Dosecann to commercialize branded versions of the products, targeting specific markets and with different cannabinoid profiles.

Dosecann will receive royalty payments from Emblem on sales of Emblem-branded products and Emblem with receive royalties from Dosecann on sales of Dosecann-branded products.

“There is substantial evidence that cannabinoids are effective for the treatment of a number of conditions including chronic pain, nausea, and spasticity in patients with Multiple Sclerosis,” says John Stewart, President of Emblem’s Pharmaceutical Division. “These advanced dosage forms and the whole strain extracts they contain are designed and formulated to enhance the therapeutic benefits available from medical cannabis.”

About Emblem
Emblem Corp. is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR (Access to Cannabis for Medical Purposes Regulations). Led by a team of cannabis experts and former health care and pharma executives, it has three distinct verticals – cannabis production, patient education centers, and pharmaceutical dosage form development. Emblem trades under the ticker symbol EMC on Toronto Venture Exchange (TSXV).

About Dosecann
Dosecann Inc. is a PEI-based Licensed Dealer applicant currently completing the buildout of a 45,000 square foot GMP compliant facility. Within the purpose-built facility, Dosecann intends to accommodate product development, extraction, formulation, filling and packaging. Dosecann is developing a suite of cannabis products across a variety of delivery methods for both the medical and adult use markets.

Forward-looking statements

This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation (together, “forward-looking statements”). All statements and information contained herein that is not clearly historical in nature may constitute forward-looking statement. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements.

Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified in the Company’s annual information form dated October 18, 2017 which has been filed with the Canadian Securities Administrators and is available on www.sedar.com. Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.

Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties and believes such information to be accurate but has not independently verified such information.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information contact:

Ali Mahdavi
Vice President, Capital Markets and Investor Relations
Emblem Corp.
(416) 962-3300
alimahdavi@emblemcorp.com

Michael Curtis
Vice President, Corporate Development
Dosecann Inc.
(416) 315-1895
Michael.curtis@dosecann.com

Thursday, December 21st, 2017 Uncategorized Comments Off on $EMMBF and Dosecann Inc. Sign Licensing Deal to Develop Dosage-Controlled Formulations